☰

Wim van den Brink, Ph.D. M.D. - Publications

Affiliations: 
Psychiatry Academic Medical Center Amsterdam, Amsterdam, Netherlands 
Area:
Addiction
Website:
https://www.amc.nl/web/research/who-is-who-in-research/who-is-who-in-research.htm?p=384
Tree Info Grants Similar researchers PubMed Report error

185/500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Migchels C, Zerrouk A, Crunelle CL, Matthys F, Gremeaux L, Fernandez K, Antoine J, van den Brink W, Vanderplasschen W. Patient Reported Outcome and Experience Measures (PROMs and PREMs) in substance use disorder treatment services: A scoping review. Drug and Alcohol Dependence. 253: 111017. PMID 37995391 DOI: 10.1016/j.drugalcdep.2023.111017  0.578
2022 Brynte C, Aeschlimann M, Barta C, Begeman AHA, Bäcker A, Crunelle CL, Daigre C, De Fuentes-Merillas L, Demetrovics Z, Dom G, López LG, Icick R, Johnson B, Joostens P, Kapitány-Fövény M, ... ... van den Brink W, et al. The clinical course of comorbid substance use disorder and attention deficit/hyperactivity disorder: protocol and clinical characteristics of the INCAS study. Bmc Psychiatry. 22: 625. PMID 36151539 DOI: 10.1186/s12888-022-04259-6  0.598
2021 Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van de Glind G, Banaschewski T, Barta C, Begeman A, Casas M, Crunelle CL, Daigre Blanco C, Dalsgaard S, Demetrovics Z, den Boer J, ... ... van den Brink W, et al. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder]. Zeitschrift Fur Kinder- Und Jugendpsychiatrie Und Psychotherapie. PMID 34397296 DOI: 10.1024/1422-4917/a000828  0.596
2021 Pape L, van Lith K, Veltman D, Cohn M, Marhe R, van den Brink W, Doreleijers T, Popma A. Effect of Methylphenidate on Resting-State Connectivity in Adolescents With a Disruptive Behavior Disorder: A Double-Blind Randomized Placebo-Controlled fMRI Study. Frontiers in Psychiatry. 12: 662652. PMID 34220576 DOI: 10.3389/fpsyt.2021.662652  0.586
2021 Marees AT, Smit DJA, Abdellaoui A, Nivard MG, van den Brink W, Denys D, Galama TJ, Verweij KJH, Derks EM. Genetic correlates of socio-economic status influence the pattern of shared heritability across mental health traits. Nature Human Behaviour. PMID 33686200 DOI: 10.1038/s41562-021-01053-4  0.522
2021 Abdellaoui A, Smit DJA, van den Brink W, Denys D, Verweij KJH. Genomic relationships across psychiatric disorders including substance use disorders. Drug and Alcohol Dependence. 220: 108535. PMID 33524898 DOI: 10.1016/j.drugalcdep.2021.108535  0.562
2020 Kapitány-Fövény M, Barta C, Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Coetzee C, Luderer M, Schellekens A, Matthys F, Demetrovics Z. [Recommendations for the screening, diagnosis and treatment of patients with comorbid attention deficit hyperactivity- and substance use disorder]. Psychiatria Hungarica : a Magyar Pszichiatriai Tarsasag Tudomanyos Folyoirata. 35: 435-447. PMID 33263293  0.6
2020 Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens ASA, van den Glind G, Banaschewski T, Barta C, Begeman A, Casas M, Crunelle CL, Daigre Blanco C, Dalsgaard S, Demetrovics Z, den Boer J, ... ... van den Brink W, et al. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. European Addiction Research. 1-10. PMID 32634814 DOI: 10.1159/000508385  0.593
2020 Schellekens AFA, van den Brink W, Kiefer F, Goudriaan AE. Often Overlooked and Ignored, but Do Not Underestimate Its Relevance: ADHD in Addiction - Addiction in ADHD. European Addiction Research. 1-4. PMID 32615559 DOI: 10.1159/000509267  0.637
2020 Van de Glind G, Brynte C, Skutle A, Kaye S, Konstenius M, Levin F, Mathys F, Demetrovics Z, Moggi F, Ramos-Quiroga JA, Schellekens A, Crunelle C, Dom G, van den Brink W, Franck J. The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities. European Addiction Research. 1-6. PMID 32599579 DOI: 10.1159/000508870  0.596
2020 Palma-Álvarez RF, Barta C, Carpentier PJ, Carruthers S, Crunelle CL, Demetrovics Z, Dom G, Faraone SV, Franck J, Johnson B, Kapitány-Fövény M, Kaye S, Konstenius M, Matthys F, Moggi F, ... ... van den Brink W, et al. Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. Revista De Psiquiatria Y Salud Mental. PMID 32561156 DOI: 10.1016/J.Rpsm.2020.04.013  0.585
2019 van Emmerik-van Oortmerssen K, Blankers M, Vedel E, Kramer F, Goudriaan AE, van den Brink W, Schoevers RA. Prediction of drop-out and outcome in integrated cognitive behavioral therapy for ADHD and SUD: Results from a randomized clinical trial. Addictive Behaviors. 103: 106228. PMID 31838443 DOI: 10.1016/J.Addbeh.2019.106228  0.663
2019 Jansen JM, van den Heuvel OA, van der Werf YD, de Wit SJ, Veltman DJ, van den Brink W, Goudriaan AE. The Effect of High-Frequency Repetitive Transcranial Magnetic Stimulation on Emotion Processing, Reappraisal, and Craving in Alcohol Use Disorder Patients and Healthy Controls: A Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry. 10: 272. PMID 31133889 DOI: 10.3389/Fpsyt.2019.00272  0.801
2019 Jansen JM, van den Heuvel OA, van der Werf YD, de Wit SJ, Veltman DJ, van den Brink W, Goudriaan AE. Emotion Processing, Reappraisal, and Craving in Alcohol Dependence: A Functional Magnetic Resonance Imaging Study. Frontiers in Psychiatry. 10: 227. PMID 31057439 DOI: 10.3389/Fpsyt.2019.00227  0.79
2019 Luigjes J, Lorenzetti V, de Haan S, Youssef GJ, Murawski C, Sjoerds Z, van den Brink W, Denys D, Fontenelle LF, Yücel M. Defining Compulsive Behavior. Neuropsychology Review. 29: 4-13. PMID 31016439 DOI: 10.1007/S11065-019-09404-9  0.775
2019 van der Burg D, Crunelle CL, Matthys F, van den Brink W. Diagnosis and treatment of patients with comorbid substance use disorder and adult attention-deficit and hyperactivity disorder: a review of recent publications. Current Opinion in Psychiatry. PMID 31008730 DOI: 10.1097/YCO.0000000000000513  0.603
2019 Marees AT, Smit DJA, Ong JS, MacGregor S, An J, Denys D, Vorspan F, van den Brink W, Derks EM. Potential influence of socioeconomic status on genetic correlations between alcohol consumption measures and mental health. Psychological Medicine. 1-15. PMID 30874500 DOI: 10.1017/S0033291719000357  0.582
2018 van Lith K, Veltman DJ, Cohn MD, Pape LE, van den Akker-Nijdam ME, van Loon AWG, Bet P, van Wingen GA, van den Brink W, Doreleijers T, Popma A. Effects of Methylphenidate During Fear Learning in Antisocial Adolescents: A Randomized Controlled fMRI Trial. Journal of the American Academy of Child and Adolescent Psychiatry. 57: 934-943. PMID 30522739 DOI: 10.1016/J.Jaac.2018.06.026  0.571
2018 de Waal MM, Dekker JJM, Kikkert MJ, Christ C, Chmielewska J, Staats MWM, van den Brink W, Goudriaan AE. Self-wise, Other-wise, Streetwise (SOS) training, an intervention to prevent victimization in dual diagnosis patients: results from a randomized clinical trial. Addiction (Abingdon, England). PMID 30461111 DOI: 10.1111/add.14500  0.635
2018 Yücel M, Oldenhof E, Ahmed S, Belin D, Billieux J, Bowden-Jones H, Carter A, Chamberlain SR, Clark L, Connor J, Daglish M, Dom G, Dannon P, Duka T, Fernandez-Serrano MJ, ... ... van den Brink W, et al. A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. Addiction (Abingdon, England). PMID 30133930 DOI: 10.1111/Add.14424  0.772
2018 Marees AT, Hammerschlag AR, Bastarache L, de Kluiver H, Vorspan F, van den Brink W, Smit DJ, Denys D, Gamazon ER, Li-Gao R, Breetvelt EJ, de Groot MCH, Galesloot TE, Vermeulen SH, Poppelaars JL, et al. Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. Drug and Alcohol Dependence. 188: 94-101. PMID 29758381 DOI: 10.1016/J.Drugalcdep.2018.03.026  0.57
2018 Kaag AM, Schulte MHJ, Jansen JM, van Wingen G, Homberg J, van den Brink W, Wiers RW, Schmaal L, Goudriaan AE, Reneman L. The relation between gray matter volume and the use of alcohol, tobacco, cocaine and cannabis in male polysubstance users. Drug and Alcohol Dependence. 187: 186-194. PMID 29679913 DOI: 10.1016/J.Drugalcdep.2018.03.010  0.788
2018 Schulte MHJ, Wiers RW, Boendermaker WJ, Goudriaan AE, van den Brink W, van Deursen DS, Friese M, Brede E, Waters AJ. Reprint of The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. Addictive Behaviors. PMID 29661657 DOI: 10.1016/j.addbeh.2018.03.023  0.673
2018 Kaag AM, Reneman L, Homberg J, van den Brink W, van Wingen GA. Enhanced Amygdala-Striatal Functional Connectivity during the Processing of Cocaine Cues in Male Cocaine Users with a History of Childhood Trauma. Frontiers in Psychiatry. 9: 70. PMID 29593581 DOI: 10.3389/Fpsyt.2018.00070  0.768
2018 Crunelle CL, van den Brink W, Moggi F, Konstenius M, Franck J, Levin FR, van de Glind G, Demetrovics Z, Coetzee C, Luderer M, Schellekens A, Matthys F. International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit/Hyperactivity Disorder. European Addiction Research. 24: 43-51. PMID 29510390 DOI: 10.1159/000487767  0.598
2018 de Waal MM, Christ C, Dekker JJM, Kikkert MJ, Lommerse NM, van den Brink W, Goudriaan AE. Factors associated with victimization in dual diagnosis patients. Journal of Substance Abuse Treatment. 84: 68-77. PMID 29195595 DOI: 10.1016/j.jsat.2017.11.001  0.661
2017 Schulte MHJ, Wiers RW, Boendermaker WJ, Goudriaan AE, van den Brink W, van Deursen DS, Friese M, Brede E, Waters AJ. The effect of N-acetylcysteine and working memory training on cocaine use, craving and inhibition in regular cocaine users: correspondence of lab assessments and Ecological Momentary Assessment. Addictive Behaviors. 79: 24-31. PMID 29241082 DOI: 10.1016/J.Addbeh.2017.11.044  0.673
2017 Schluter RS, Jansen JM, van Holst RJ, van den Brink W, Goudriaan AE. Differential effects of left and right prefrontal high frequency rTMS on resting state fMRI in healthy individuals. Brain Connectivity. PMID 29237276 DOI: 10.1089/brain.2017.0542  0.777
2017 Schulte M, Goudriaan AE, Kaag AM, Kooi DP, van den Brink W, Wiers RW, Schmaal L. The effect of N-acetylcysteine on brain glutamate and gamma-aminobutyric acid concentrations and on smoking cessation: A randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 269881117730660. PMID 28922968 DOI: 10.1177/0269881117730660  0.772
2017 Schulte MHJ, Kaag AM, Wiers RW, Schmaal L, van den Brink W, Reneman L, Homberg JR, van Wingen GA, Goudriaan AE. Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. Drug and Alcohol Dependence. 179: 117-123. PMID 28763779 DOI: 10.1016/J.Drugalcdep.2017.06.025  0.785
2017 Koenders L, Lorenzetti V, de Haan L, Suo C, Vingerhoets W, van den Brink W, Wiers RW, Meijer CJ, Machielsen M, Goudriaan AE, Veltman DJ, Yücel M, Cousijn J. Longitudinal study of hippocampal volumes in heavy cannabis users. Journal of Psychopharmacology (Oxford, England). 269881117718380. PMID 28741422 DOI: 10.1177/0269881117718380  0.561
2017 Beraha EM, Salemink E, Goudriaan AE, van den Brink W, Wiers RW. Response to "Baclofen and alcohol use disorders: From miracle to mirage". European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 28576349 DOI: 10.1016/j.euroneuro.2017.05.002  0.679
2017 Machielsen MW, Veltman DJ, van den Brink W, de Haan L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. Schizophrenia Research. PMID 28351544 DOI: 10.1016/J.Schres.2017.03.030  0.567
2016 Gevonden M, Myin-Germeys I, Wichers M, Booij J, van den Brink W, van Winkel R, Selten JP. Reactivity to social stress in ethnic minority men. Psychiatry Research. PMID 27884461 DOI: 10.1016/J.Psychres.2016.10.076  0.369
2016 Mattila T, Koeter M, Wohlfarth T, Storosum J, van den Brink W, Derks E, Leufkens H, Denys D. The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 27842941 DOI: 10.1016/J.Euroneuro.2016.10.004  0.555
2016 Beraha EM, Salemink E, Goudriaan AE, Bakker A, de Jong D, Smits N, Zwart JW, Geest DV, Bodewits P, Schiphof T, Defourny H, van Tricht M, van den Brink W, Wiers RW. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 27842939 DOI: 10.1016/j.euroneuro.2016.10.006  0.64
2016 Welten CC, Koeter MW, Wohlfarth TD, Storosum JG, van den Brink W, Gispen-de Wied CC, Leufkens HG, Denys DA. Early Nonresponse in the Antipsychotic Treatment of Acute Mania: A Criterion for Reconsidering Treatment? Results From an Individual Patient Data Meta-Analysis. The Journal of Clinical Psychiatry. 77: e1117-e1123. PMID 27780320 DOI: 10.4088/JCP.15r10051  0.534
2016 Zaaijer ER, Goudriaan AE, Koeter MW, Booij J, van den Brink W. Acceptability of Extended-Release Naltrexone by Heroin-Dependent Patients and Addiction Treatment Providers in the Netherlands. Substance Use & Misuse. 1-7. PMID 27613150 DOI: 10.1080/10826084.2016.1201117  0.779
2016 Kaag AM, Schluter RS, Karel P, Homberg J, van den Brink W, Reneman L, van Wingen GA. Aversive Counterconditioning Attenuates Reward Signaling in the Ventral Striatum. Frontiers in Human Neuroscience. 10: 418. PMID 27594829 DOI: 10.3389/Fnhum.2016.00418  0.761
2016 Cohn MD, Viding E, McCrory E, Pape L, van den Brink W, Doreleijers TA, Veltman DJ, Popma A. Regional grey matter volume and concentration in at-risk adolescents: Untangling associations with callous-unemotional traits and conduct disorder symptoms. Psychiatry Research. 254: 180-187. PMID 27479922 DOI: 10.1016/J.Pscychresns.2016.07.003  0.54
2016 Luigjes J, Figee M, Tobler PN, van den Brink W, de Kwaasteniet B, van Wingen G, Denys D. Doubt in the Insula: Risk Processing in Obsessive-Compulsive Disorder. Frontiers in Human Neuroscience. 10: 283. PMID 27378883 DOI: 10.3389/Fnhum.2016.00283  0.782
2016 Koenders L, Cousijn J, Vingerhoets WA, van den Brink W, Wiers RW, Meijer CJ, Machielsen MW, Veltman DJ, Goudriaan AE, de Haan L. Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. Plos One. 11: e0152482. PMID 27224247 DOI: 10.1371/Journal.Pone.0152482  0.797
2016 Nuijten M, Blanken P, Van den Brink W, Goudriaan AE, Hendriks VM. Impulsivity and attentional bias as predictors of modafinil treatment outcome for retention and drug use in crack-cocaine dependent patients: Results of a randomised controlled trial. Journal of Psychopharmacology (Oxford, England). PMID 27147591 DOI: 10.1177/0269881116645268  0.671
2016 Kaag AM, Levar N, Woutersen K, Homberg J, van den Brink W, Reneman L, van Wingen G. Hyperresponsiveness of the Neural Fear Network During Fear Conditioning and Extinction Learning in Male Cocaine Users. The American Journal of Psychiatry. appiajp201615040433. PMID 27079132 DOI: 10.1176/Appi.Ajp.2016.15040433  0.762
2016 Kaye S, Ramos-Quiroga JA, van de Glind G, Levin FR, Faraone SV, Allsop S, Degenhardt L, Moggi F, Barta C, Konstenius M, Franck J, Skutle A, Bu ET, Koeter MW, Demetrovics Z, ... ... van den Brink W, et al. Persistence and Subtype Stability of ADHD Among Substance Use Disorder Treatment Seekers. Journal of Attention Disorders. PMID 26922805 DOI: 10.1177/1087054716629217  0.594
2016 Kaag AM, van Wingen GA, Caan MW, Homberg JR, van den Brink W, Reneman L. White matter alterations in cocaine users are negatively related to the number of additionally (ab)used substances. Addiction Biology. PMID 26860848 DOI: 10.1111/Adb.12375  0.774
2015 Figee M, Pattij T, Willuhn I, Luigjes J, van den Brink W, Goudriaan A, Potenza MN, Robbins TW, Denys D. Compulsivity in obsessive-compulsive disorder and addictions. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 26774279 DOI: 10.1016/J.Euroneuro.2015.12.003  0.802
2015 Sjoerds Z, Stufflebeam SM, Veltman DJ, Van den Brink W, Penninx BW, Douw L. Loss of brain graph network efficiency in alcohol dependence. Addiction Biology. PMID 26692359 DOI: 10.1111/Adb.12346  0.791
2015 Welten CC, Koeter MW, Wohlfarth TD, Storosum JG, van den Brink W, Gispen-de Wied CC, Leufkens HG, Denys DA. Does Insight Affect the Efficacy of Antipsychotics in Acute Mania?: An Individual Patient Data Regression Meta-Analysis. Journal of Clinical Psychopharmacology. PMID 26647231 DOI: 10.1097/JCP.0000000000000435  0.572
2015 Vingerhoets W, Koenders L, van den Brink W, Wiers RW, Goudriaan AE, van Amelsvoort T, de Haan L, Cousijn J. Cue-induced striatal activity in frequent cannabis users independently predicts cannabis problem severity three years later. Journal of Psychopharmacology (Oxford, England). PMID 26645206 DOI: 10.1177/0269881115620436  0.779
2015 Pape LE, Cohn MD, Caan MW, van Wingen G, van den Brink W, Veltman DJ, Popma A. Psychopathic traits in adolescents are associated with higher structural connectivity. Psychiatry Research. 233: 474-80. PMID 26272037 DOI: 10.1016/J.Pscychresns.2015.07.023  0.542
2015 Stringer S, Cerrone KC, van den Brink W, van den Berg JF, Denys D, Kahn RS, Derks EM. A guide on gene prioritization in studies of psychiatric disorders. International Journal of Methods in Psychiatric Research. PMID 26230968 DOI: 10.1002/Mpr.1482  0.538
2015 Crunelle CL, Kaag AM, van den Munkhof HE, Reneman L, Homberg JR, Sabbe B, van den Brink W, van Wingen G. Dysfunctional amygdala activation and connectivity with the prefrontal cortex in current cocaine users. Human Brain Mapping. 36: 4222-30. PMID 26220024 DOI: 10.1002/Hbm.22913  0.797
2015 Welten CC, Koeter MW, Wohlfarth TD, Storosum JG, van den Brink W, Gispen-de Wied CC, Leufkens HG, Denys DA. Net gain analysis, an addition to responder analysis - The case of antipsychotic treatment of acute mania. Regulatory Toxicology and Pharmacology : Rtp. 73: 227-31. PMID 26164267 DOI: 10.1016/j.yrtph.2015.06.020  0.54
2015 Welten CC, Koeter MW, Wohlfarth TD, Storosum JG, van den Brink W, Gispen-de Wied CC, Leufkens HG, Denys DA. Efficacy of drug treatment for acute mania differs across geographic regions: An individual patient data meta-analysis of placebo-controlled studies. Journal of Psychopharmacology (Oxford, England). 29: 923-32. PMID 26038109 DOI: 10.1177/0269881115586938  0.573
2015 Welten CC, Koeter MW, Wohlfarth T, Storosum JG, van den Brink W, Gispen-de Wied CC, Leufkens HG, Denys DA. Placebo response in antipsychotic trials of patients with acute mania: Results of an individual patient data meta-analysis. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 25: 1018-26. PMID 25907248 DOI: 10.1016/j.euroneuro.2015.03.010  0.567
2015 Luigjes J, van den Brink W, Schuurman PR, Kuhn J, Denys D. Is deep brain stimulation a treatment option for addiction? Addiction (Abingdon, England). 110: 547-8. PMID 25771687 DOI: 10.1111/Add.12773  0.747
2015 Cohn MD, Pape LE, Schmaal L, van den Brink W, van Wingen G, Vermeiren RR, Doreleijers TA, Veltman DJ, Popma A. Differential relations between juvenile psychopathic traits and resting state network connectivity. Human Brain Mapping. 36: 2396-405. PMID 25757797 DOI: 10.1002/Hbm.22779  0.746
2015 Zaaijer ER, van Dijk L, de Bruin K, Goudriaan AE, Lammers LA, Koeter MW, van den Brink W, Booij J. Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. Psychopharmacology. 232: 2597-607. PMID 25757673 DOI: 10.1007/S00213-015-3891-4  0.786
2015 Zaaijer ER, de Bruin K, la Fleur SE, Goudriaan AE, van den Brink W, Booij J. Subchronic administration of short-acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats. Journal of Psychopharmacology (Oxford, England). 29: 344-8. PMID 25586403 DOI: 10.1177/0269881114565380  0.778
2015 Mattila T, Koeter M, Wohlfarth T, Storosum J, van den Brink W, de Haan L, Derks E, Leufkens H, Denys D. Impact of DSM-5 changes on the diagnosis and acute treatment of schizophrenia. Schizophrenia Bulletin. 41: 637-43. PMID 25528758 DOI: 10.1093/Schbul/Sbu172  0.54
2015 Koenders L, Machielsen MW, van der Meer FJ, van Gasselt AC, Meijer CJ, van den Brink W, Koeter MW, Caan MW, Cousijn J, den Braber A, van 't Ent D, Rive MM, Schene AH, van de Giessen E, Huyser C, et al. Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. Journal of Psychiatry & Neuroscience : Jpn. 40: 197-206. PMID 25510948 DOI: 10.1503/Jpn.140081  0.784
2015 Gevonden MJ, Myin-Germeys I, van den Brink W, van Os J, Selten JP, Booij J. Psychotic reactions to daily life stress and dopamine function in people with severe hearing impairment. Psychological Medicine. 45: 1665-74. PMID 25482840 DOI: 10.1017/S0033291714002797  0.435
2015 Bongers P, van de Giessen E, Roefs A, Nederkoorn C, Booij J, van den Brink W, Jansen A. Being impulsive and obese increases susceptibility to speeded detection of high-calorie foods. Health Psychology : Official Journal of the Division of Health Psychology, American Psychological Association. 34: 677-85. PMID 25365413 DOI: 10.1037/Hea0000167  0.672
2015 Heytens L, Neels H, Van Regenmortel N, van den Brink W, Henckes M, Schouwers S, Dockx G, Crunelle CL. Near-fatal persistent anion- and osmolal-gap acidosis due to massive gamma-butyrolactone/ethanol intoxication. Annals of Clinical Biochemistry. 52: 283-7. PMID 25205856 DOI: 10.1177/0004563214553278  0.538
2015 Jansen JM, van der Werf YD, van den Heuvel OA, de Wit SJ, van den Brink W, Goudriaan AE. Niet-invasieve hersenstimulatie bij verslaving; het effect op craving en emotieregulatie Neuropraxis. 19: 54-58. DOI: 10.1007/s12474-015-0080-5  0.631
2014 Cohn MD, Veltman DJ, Pape LE, van Lith K, Vermeiren RR, van den Brink W, Doreleijers TA, Popma A. Incentive Processing in Persistent Disruptive Behavior and Psychopathic Traits: A Functional Magnetic Resonance Imaging Study in Adolescents. Biological Psychiatry. PMID 25497690 DOI: 10.1016/J.Biopsych.2014.08.017  0.55
2014 Jansen JM, van Holst RJ, van den Brink W, Veltman DJ, Caan MW, Goudriaan AE. Brain function during cognitive flexibility and white matter integrity in alcohol-dependent patients, problematic drinkers and healthy controls. Addiction Biology. PMID 25477246 DOI: 10.1111/Adb.12199  0.801
2014 Zaaijer ER, Bruijel J, Blanken P, Hendriks V, Koeter MW, Kreek MJ, Booij J, Goudriaan AE, van Ree JM, van den Brink W. Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. Drug and Alcohol Dependence. 145: 101-5. PMID 25454407 DOI: 10.1016/J.Drugalcdep.2014.09.783  0.764
2014 Romanczuk-Seiferth N, van den Brink W, Goudriaan AE. From symptoms to neurobiology: pathological gambling in the light of the new classification in DSM-5. Neuropsychobiology. 70: 95-102. PMID 25359489 DOI: 10.1159/000362839  0.676
2014 Merkx MJ, Schippers GM, Koeter MW, De Wildt WA, Vedel E, Goudriaan AE, Van Den Brink W. Treatment outcome of alcohol use disorder outpatients with or without medically assisted detoxification. Journal of Studies On Alcohol and Drugs. 75: 993-8. PMID 25343657 DOI: 10.15288/jsad.2014.75.993  0.673
2014 Kaag AM, Crunelle CL, van Wingen G, Homberg J, van den Brink W, Reneman L. Relationship between trait impulsivity and cortical volume, thickness and surface area in male cocaine users and non-drug using controls. Drug and Alcohol Dependence. 144: 210-7. PMID 25278147 DOI: 10.1016/J.Drugalcdep.2014.09.016  0.787
2014 Gevonden M, Booij J, van den Brink W, Heijtel D, van Os J, Selten JP. Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia. Jama Psychiatry. 71: 1364-72. PMID 25271822 DOI: 10.1001/Jamapsychiatry.2014.1325  0.399
2014 Schulte MH, Cousijn J, den Uyl TE, Goudriaan AE, van den Brink W, Veltman DJ, Schilt T, Wiers RW. Recovery of neurocognitive functions following sustained abstinence after substance dependence and implications for treatment. Clinical Psychology Review. 34: 531-50. PMID 25240109 DOI: 10.1016/J.Cpr.2014.08.002  0.794
2014 Schmaal L, Goudriaan AE, Joos L, Dom G, Pattij T, van den Brink W, Veltman DJ. Neural substrates of impulsive decision making modulated by modafinil in alcohol-dependent patients. Psychological Medicine. 44: 2787-98. PMID 25066449 DOI: 10.1017/S0033291714000312  0.799
2014 van Holst RJ, Clark L, Veltman DJ, van den Brink W, Goudriaan AE. Enhanced striatal responses during expectancy coding in alcohol dependence. Drug and Alcohol Dependence. 142: 204-8. PMID 25012896 DOI: 10.1016/J.Drugalcdep.2014.06.019  0.79
2014 Kräplin A, Bühringer G, Oosterlaan J, van den Brink W, Goschke T, Goudriaan AE. Dimensions and disorder specificity of impulsivity in pathological gambling. Addictive Behaviors. 39: 1646-51. PMID 24930455 DOI: 10.1016/J.Addbeh.2014.05.021  0.681
2014 Vanes LD, van Holst RJ, Jansen JM, van den Brink W, Oosterlaan J, Goudriaan AE. Contingency learning in alcohol dependence and pathological gambling: learning and unlearning reward contingencies. Alcoholism, Clinical and Experimental Research. 38: 1602-10. PMID 24821534 DOI: 10.1111/Acer.12393  0.771
2014 van de Giessen E, Celik F, Schweitzer DH, van den Brink W, Booij J. Dopamine D2/3 receptor availability and amphetamine-induced dopamine release in obesity. Journal of Psychopharmacology (Oxford, England). 28: 866-73. PMID 24785761 DOI: 10.1177/0269881114531664  0.665
2014 Crunelle CL, van den Brink W, Dom G, Booij J. Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. The British Journal of Psychiatry : the Journal of Mental Science. 204: 486-7. PMID 24676965 DOI: 10.1192/Bjp.Bp.113.132977  0.66
2014 Mattila T, Wohlfarth T, Koeter M, Storosum J, van den Brink W, de Haan L, Leufkens H, Denys D. Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia - an individual patient data meta-analysis. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 24: 1067-77. PMID 24661547 DOI: 10.1016/J.Euroneuro.2014.02.006  0.547
2014 Machielsen MW, Veltman DJ, van den Brink W, de Haan L. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of Psychopharmacology (Oxford, England). 28: 633-642. PMID 24646809 DOI: 10.1177/0269881114527357  0.582
2014 Cousijn J, Vingerhoets WA, Koenders L, de Haan L, van den Brink W, Wiers RW, Goudriaan AE. Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. Addiction Biology. 19: 282-93. PMID 24589297 DOI: 10.1111/Adb.12111  0.763
2014 Sjoerds Z, Luigjes J, van den Brink W, Denys D, Yücel M. The role of habits and motivation in human drug addiction: a reflection. Frontiers in Psychiatry. 5: 8. PMID 24523702 DOI: 10.3389/Fpsyt.2014.00008  0.782
2014 Boschloo L, van den Brink W, Penninx BW. Does self-medication predict the persistence or rather the recurrence of alcohol dependence? Jama Psychiatry. 71: 205. PMID 24500625 DOI: 10.1001/jamapsychiatry.2013.2985  0.481
2014 Crunelle CL, Kaag AM, van Wingen G, van den Munkhof HE, Homberg JR, Reneman L, van den Brink W. Reduced frontal brain volume in non-treatment-seeking cocaine-dependent individuals: exploring the role of impulsivity, depression, and smoking. Frontiers in Human Neuroscience. 8: 7. PMID 24478673 DOI: 10.3389/Fnhum.2014.00007  0.795
2014 Sjoerds Z, van den Brink W, Beekman AT, Penninx BW, Veltman DJ. Cue reactivity is associated with duration and severity of alcohol dependence: an FMRI study. Plos One. 9: e84560. PMID 24400099 DOI: 10.1371/Journal.Pone.0084560  0.803
2014 Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Effect of baseline cannabis use and working-memory network function on changes in cannabis use in heavy cannabis users: a prospective fMRI study. Human Brain Mapping. 35: 2470-82. PMID 24038570 DOI: 10.1002/Hbm.22342  0.787
2014 Sjoerds Z, van den Brink W, Beekman AT, Penninx BW, Veltman DJ. Response inhibition in alcohol-dependent patients and patients with depression/anxiety: a functional magnetic resonance imaging study. Psychological Medicine. 44: 1713-25. PMID 24016382 DOI: 10.1017/S0033291713002274  0.8
2013 Boschloo L, Vogelzangs N, van den Brink W, Smit JH, Veltman DJ, Beekman AT, Penninx BW. Depressive and anxiety disorders predicting first incidence of alcohol use disorders: results of the Netherlands Study of Depression and Anxiety (NESDA). The Journal of Clinical Psychiatry. 74: 1233-40. PMID 24434092 DOI: 10.4088/Jcp.12M08159  0.696
2013 Sjoerds Z, de Wit S, van den Brink W, Robbins TW, Beekman AT, Penninx BW, Veltman DJ. Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients. Translational Psychiatry. 3: e337. PMID 24346135 DOI: 10.1038/Tp.2013.107  0.803
2013 Cohn MD, Popma A, van den Brink W, Pape LE, Kindt M, van Domburgh L, Doreleijers TA, Veltman DJ. Fear conditioning, persistence of disruptive behavior and psychopathic traits: an fMRI study. Translational Psychiatry. 3: e319. PMID 24169638 DOI: 10.1038/Tp.2013.89  0.581
2013 Joos L, Goudriaan AE, Schmaal L, van den Brink W, Sabbe BG, Dom G. Effect of modafinil on cognitive functions in alcohol dependent patients: a randomized, placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 27: 998-1006. PMID 24045883 DOI: 10.1177/0269881113503505  0.788
2013 Jansen JM, Daams JG, Koeter MW, Veltman DJ, van den Brink W, Goudriaan AE. Effects of non-invasive neurostimulation on craving: a meta-analysis. Neuroscience and Biobehavioral Reviews. 37: 2472-80. PMID 23916527 DOI: 10.1016/J.Neubiorev.2013.07.009  0.784
2013 Crunelle CL, van den Brink W, Veltman DJ, van Emmerik-van Oortmerssen K, Dom G, Schoevers RA, Booij J. Low dopamine transporter occupancy by methylphenidate as a possible reason for reduced treatment effectiveness in ADHD patients with cocaine dependence. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1714-23. PMID 23731497 DOI: 10.1016/J.Euroneuro.2013.05.002  0.764
2013 van Wingen GA, van den Brink W, Veltman DJ, Schmaal L, Dom G, Booij J, Crunelle CL. Reduced striatal brain volumes in non-medicated adult ADHD patients with comorbid cocaine dependence. Drug and Alcohol Dependence. 131: 198-203. PMID 23726981 DOI: 10.1016/J.Drugalcdep.2013.05.007  0.794
2013 Starcke K, van Holst RJ, van den Brink W, Veltman DJ, Goudriaan AE. Physiological and endocrine reactions to psychosocial stress in alcohol use disorders: duration of abstinence matters. Alcoholism, Clinical and Experimental Research. 37: 1343-50. PMID 23488992 DOI: 10.1111/Acer.12103  0.783
2013 Figee M, Luigjes J, Smolders R, Valencia-Alfonso CE, van Wingen G, de Kwaasteniet B, Mantione M, Ooms P, de Koning P, Vulink N, Levar N, Droge L, van den Munckhof P, Schuurman PR, Nederveen A, ... van den Brink W, et al. Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nature Neuroscience. 16: 386-7. PMID 23434914 DOI: 10.1038/Nn.3344  0.796
2013 Schmaal L, Goudriaan AE, Joos L, Krüse AM, Dom G, van den Brink W, Veltman DJ. Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. Biological Psychiatry. 73: 789-95. PMID 23399373 DOI: 10.1016/J.Biopsych.2012.12.025  0.796
2013 Schouw ML, De Ruiter MB, Kaag AM, van den Brink W, Lindauer RJ, Reneman L. Dopaminergic dysfunction in abstinent dexamphetamine users: results from a pharmacological fMRI study using a reward anticipation task and a methylphenidate challenge. Drug and Alcohol Dependence. 130: 52-60. PMID 23142493 DOI: 10.1016/J.Drugalcdep.2012.10.010  0.776
2013 Joos L, Goudriaan AE, Schmaal L, Fransen E, van den Brink W, Sabbe BG, Dom G. Effect of modafinil on impulsivity and relapse in alcohol dependent patients: a randomized, placebo-controlled trial. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 948-55. PMID 23141152 DOI: 10.1016/J.Euroneuro.2012.10.004  0.803
2013 Joos L, Goudriaan AE, Schmaal L, De Witte NA, Van den Brink W, Sabbe BG, Dom G. The relationship between impulsivity and craving in alcohol dependent patients. Psychopharmacology. 226: 273-83. PMID 23096771 DOI: 10.1007/S00213-012-2905-8  0.804
2013 Sjoerds Z, van Tol MJ, van den Brink W, van der Wee NJ, Aleman A, Beekman AT, Penninx BW, Veltman DJ. Family history of alcohol dependence modulates functional neurophysiology in mood/anxiety disorders. Psychological Medicine. 43: 1487-97. PMID 23036336 DOI: 10.1017/S003329171200222X  0.808
2013 Crunelle CL, Veltman DJ, van Emmerik-van Oortmerssen K, Booij J, van den Brink W. Impulsivity in adult ADHD patients with and without cocaine dependence. Drug and Alcohol Dependence. 129: 18-24. PMID 23026814 DOI: 10.1016/J.Drugalcdep.2012.09.006  0.768
2013 Joos L, Schmaal L, Goudriaan AE, Fransen E, Van den Brink W, Sabbe BG, Dom G. Age of onset and neuropsychological functioning in alcohol dependent inpatients. Alcoholism, Clinical and Experimental Research. 37: 407-16. PMID 23025636 DOI: 10.1111/J.1530-0277.2012.01949.X  0.799
2013 Boschloo L, Vogelzangs N, van den Brink W, Smit JH, Beekman AT, Penninx BW. The role of negative emotionality and impulsivity in depressive/anxiety disorders and alcohol dependence. Psychological Medicine. 43: 1241-53. PMID 23020956 DOI: 10.1017/S0033291712002152  0.527
2013 Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Porrino LJ, Goudriaan AE. Individual differences in decision making and reward processing predict changes in cannabis use: a prospective functional magnetic resonance imaging study. Addiction Biology. 18: 1013-23. PMID 22994937 DOI: 10.1111/J.1369-1600.2012.00498.X  0.803
2013 van de Giessen E, la Fleur SE, Eggels L, de Bruin K, van den Brink W, Booij J. High fat/carbohydrate ratio but not total energy intake induces lower striatal dopamine D2/3 receptor availability in diet-induced obesity. International Journal of Obesity (2005). 37: 754-7. PMID 22868829 DOI: 10.1038/Ijo.2012.128  0.659
2013 Schmaal L, Joos L, Koeleman M, Veltman DJ, van den Brink W, Goudriaan AE. Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients. Biological Psychiatry. 73: 211-8. PMID 22858150 DOI: 10.1016/J.Biopsych.2012.06.032  0.802
2013 Goudriaan AE, Veltman DJ, van den Brink W, Dom G, Schmaal L. Neurophysiological effects of modafinil on cue-exposure in cocaine dependence: a randomized placebo-controlled cross-over study using pharmacological fMRI. Addictive Behaviors. 38: 1509-17. PMID 22591950 DOI: 10.1016/J.Addbeh.2012.04.006  0.804
2013 Sjoerds Z, Van Tol MJ, Van den Brink W, Van der Wee NJ, Van Buchem MA, Aleman A, Penninx BW, Veltman DJ. Family history of alcohol dependence and gray matter abnormalities in non-alcoholic adults. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 14: 565-73. PMID 22283466 DOI: 10.3109/15622975.2011.640942  0.795
2013 Cousijn J, Goudriaan AE, Ridderinkhof KR, van den Brink W, Veltman DJ, Wiers RW. Neural responses associated with cue-reactivity in frequent cannabis users. Addiction Biology. 18: 570-80. PMID 22264344 DOI: 10.1111/J.1369-1600.2011.00417.X  0.802
2013 Crunelle CL, van de Giessen E, Schulz S, Vanderschuren LJ, de Bruin K, van den Brink W, Booij J. Cannabinoid-1 receptor antagonist rimonabant (SR141716) increases striatal dopamine D2 receptor availability. Addiction Biology. 18: 908-11. PMID 21955259 DOI: 10.1111/J.1369-1600.2011.00369.X  0.765
2012 Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Current Drug Abuse Reviews. 5: 320-31. PMID 23244344 DOI: 10.2174/1874473711205040006  0.665
2012 van Holst RJ, van der Meer JN, McLaren DG, van den Brink W, Veltman DJ, Goudriaan AE. Interactions between affective and cognitive processing systems in problematic gamblers: a functional connectivity study. Plos One. 7: e49923. PMID 23209619 DOI: 10.1371/Journal.Pone.0049923  0.79
2012 Schmaal L, Goudriaan AE, van der Meer J, van den Brink W, Veltman DJ. The association between cingulate cortex glutamate concentration and delay discounting is mediated by resting state functional connectivity. Brain and Behavior. 2: 553-62. PMID 23139901 DOI: 10.1002/Brb3.74  0.796
2012 Cousijn J, Goudriaan AE, Ridderinkhof KR, van den Brink W, Veltman DJ, Wiers RW. Approach-bias predicts development of cannabis problem severity in heavy cannabis users: results from a prospective FMRI study. Plos One. 7: e42394. PMID 22957019 DOI: 10.1371/Journal.Pone.0042394  0.797
2012 Crunelle CL, Veltman DJ, Booij J, Emmerik-van Oortmerssen K, van den Brink W. Substrates of neuropsychological functioning in stimulant dependence: a review of functional neuroimaging research. Brain and Behavior. 2: 499-523. PMID 22950052 DOI: 10.1002/Brb3.65  0.78
2012 van Holst RJ, Veltman DJ, van den Brink W, Goudriaan AE. Right on cue? Striatal reactivity in problem gamblers. Biological Psychiatry. 72: e23-4. PMID 22795970 DOI: 10.1016/J.Biopsych.2012.06.017  0.761
2012 Reneman L, de Win MM, Booij J, van den Brink W, den Heeten GJ, Freling N, Majoie CB. Incidental head and neck findings on MRI in young healthy volunteers: prevalence and clinical implications. Ajnr. American Journal of Neuroradiology. 33: 1971-4. PMID 22723061 DOI: 10.3174/Ajnr.A3217  0.603
2012 Broos N, Schmaal L, Wiskerke J, Kostelijk L, Lam T, Stoop N, Weierink L, Ham J, de Geus EJ, Schoffelmeer AN, van den Brink W, Veltman DJ, de Vries TJ, Pattij T, Goudriaan AE. The relationship between impulsive choice and impulsive action: a cross-species translational study. Plos One. 7: e36781. PMID 22574225 DOI: 10.1371/Journal.Pone.0036781  0.787
2012 Schmaal L, Veltman DJ, Nederveen A, van den Brink W, Goudriaan AE. N-acetylcysteine normalizes glutamate levels in cocaine-dependent patients: a randomized crossover magnetic resonance spectroscopy study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 37: 2143-52. PMID 22549117 DOI: 10.1038/Npp.2012.66  0.8
2012 van Holst RJ, van Holstein M, van den Brink W, Veltman DJ, Goudriaan AE. Response inhibition during cue reactivity in problem gamblers: an fMRI study. Plos One. 7: e30909. PMID 22479305 DOI: 10.1371/Journal.Pone.0030909  0.792
2012 van de Giessen E, Nimgaonkar VL, Watson AM, Kodavali C, Baas F, Tanck MW, de Win MM, van den Brink W, Booij J. Association tests of striatal DAT availability and SNPs that impact a novel splice variant in the DAT gene. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 53: 839. PMID 22427685 DOI: 10.2967/Jnumed.111.100271  0.658
2012 Boschloo L, Vogelzangs N, van den Brink W, Smit JH, Beekman AT, Penninx BW. Predictors of the 2-year recurrence and persistence of alcohol dependence. Addiction (Abingdon, England). 107: 1639-40. PMID 22372473 DOI: 10.1111/J.1360-0443.2012.03860.X  0.532
2012 van Holst RJ, Veltman DJ, Büchel C, van den Brink W, Goudriaan AE. Distorted expectancy coding in problem gambling: is the addictive in the anticipation? Biological Psychiatry. 71: 741-8. PMID 22342105 DOI: 10.1016/J.Biopsych.2011.12.030  0.79
2012 Boschloo L, Vogelzangs N, van den Brink W, Smit JH, Veltman DJ, Beekman AT, Penninx BW. Alcohol use disorders and the course of depressive and anxiety disorders. The British Journal of Psychiatry : the Journal of Mental Science. 200: 476-84. PMID 22322459 DOI: 10.1192/Bjp.Bp.111.097550  0.694
2012 van de Giessen E, la Fleur SE, de Bruin K, van den Brink W, Booij J. Free-choice and no-choice high-fat diets affect striatal dopamine D2/3 receptor availability, caloric intake, and adiposity. Obesity (Silver Spring, Md.). 20: 1738-40. PMID 22307070 DOI: 10.1038/Oby.2012.17  0.663
2012 Valencia-Alfonso CE, Luigjes J, Smolders R, Cohen MX, Levar N, Mazaheri A, van den Munckhof P, Schuurman PR, van den Brink W, Denys D. Effective deep brain stimulation in heroin addiction: a case report with complementary intracranial electroencephalogram. Biological Psychiatry. 71: e35-7. PMID 22281120 DOI: 10.1016/J.Biopsych.2011.12.013  0.737
2012 van Holst RJ, de Ruiter MB, van den Brink W, Veltman DJ, Goudriaan AE. A voxel-based morphometry study comparing problem gamblers, alcohol abusers, and healthy controls. Drug and Alcohol Dependence. 124: 142-8. PMID 22270405 DOI: 10.1016/J.Drugalcdep.2011.12.025  0.809
2012 Crunelle CL, de Wit TC, de Bruin K, Ramakers RM, van der Have F, Beekman FJ, van den Brink W, Booij J. Varenicline increases in vivo striatal dopamine D2/3 receptor binding: an ultra-high-resolution pinhole [123I]IBZM SPECT study in rats. Nuclear Medicine and Biology. 39: 640-4. PMID 22261145 DOI: 10.1016/J.Nucmedbio.2011.11.006  0.662
2012 van Emmerik-van Oortmerssen K, van de Glind G, van den Brink W, Smit F, Crunelle CL, Swets M, Schoevers RA. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug and Alcohol Dependence. 122: 11-9. PMID 22209385 DOI: 10.1016/J.Drugalcdep.2011.12.007  0.621
2012 Veldhuis J, Dieleman JP, Wohlfarth T, Storosum JG, van Den Brink W, Sturkenboom MC, Denys D. Incidence and prevalence of "diagnosed OCD" in a primary care, treatment seeking, population. International Journal of Psychiatry in Clinical Practice. 16: 85-92. PMID 22122660 DOI: 10.3109/13651501.2011.617454  0.546
2012 Cousijn J, Wiers RW, Ridderinkhof KR, van den Brink W, Veltman DJ, Goudriaan AE. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. Neuroimage. 59: 3845-51. PMID 21982932 DOI: 10.1016/J.Neuroimage.2011.09.046  0.802
2012 Luigjes J, van den Brink W, Feenstra M, van den Munckhof P, Schuurman PR, Schippers R, Mazaheri A, De Vries TJ, Denys D. Deep brain stimulation in addiction: a review of potential brain targets. Molecular Psychiatry. 17: 572-83. PMID 21931318 DOI: 10.1038/Mp.2011.114  0.756
2012 de Ruiter MB, Oosterlaan J, Veltman DJ, van den Brink W, Goudriaan AE. Similar hyporesponsiveness of the dorsomedial prefrontal cortex in problem gamblers and heavy smokers during an inhibitory control task. Drug and Alcohol Dependence. 121: 81-9. PMID 21893386 DOI: 10.1016/J.Drugalcdep.2011.08.010  0.783
2012 van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, Booij J. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 22: 290-9. PMID 21889317 DOI: 10.1016/J.Euroneuro.2011.07.015  0.666
2012 Boschloo L, van den Brink W, Penninx BW, Wall MM, Hasin DS. Alcohol-use disorder severity predicts first-incidence of depressive disorders. Psychological Medicine. 42: 695-703. PMID 21867593 DOI: 10.1017/S0033291711001681  0.538
2012 Boschloo L, Vogelzangs N, Van Den Brink W, Smit JH, Veltman DJ, Beekman ATF, Penninx BWJH. Authors' reply: British Journal of Psychiatry. 201: 326-327. DOI: 10.1192/bjp.201.4.326a  0.475
2011 Luigjes J, Mantione M, van den Brink W, Schuurman PR, van den Munckhof P, Denys D. Deep brain stimulation increases impulsivity in two patients with obsessive-compulsive disorder. International Clinical Psychopharmacology. 26: 338-40. PMID 21857527 DOI: 10.1097/Yic.0B013E32834Af505  0.756
2011 Blom RM, Koeter M, van den Brink W, de Graaf R, Ten Have M, Denys D. Co-occurrence of obsessive-compulsive disorder and substance use disorder in the general population. Addiction (Abingdon, England). 106: 2178-85. PMID 21714825 DOI: 10.1111/J.1360-0443.2011.03559.X  0.577
2011 Schmaal L, Berk L, Hulstijn KP, Cousijn J, Wiers RW, van den Brink W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. European Addiction Research. 17: 211-6. PMID 21606648 DOI: 10.1159/000327682  0.743
2011 van de Giessen E, Groot PF, Booij J, van den Brink W, Veltman DJ, Nederveen AJ. Functional MR imaging on an open 1T MR imaging system: exploiting the advantages of an open MR imaging system for functional MR imaging. Ajnr. American Journal of Neuroradiology. 32: 903-7. PMID 21330391 DOI: 10.3174/ajnr.A2383  0.746
2011 Boschloo L, Vogelzangs N, Licht CM, Vreeburg SA, Smit JH, van den Brink W, Veltman DJ, de Geus EJ, Beekman AT, Penninx BW. Heavy alcohol use, rather than alcohol dependence, is associated with dysregulation of the hypothalamic-pituitary-adrenal axis and the autonomic nervous system. Drug and Alcohol Dependence. 116: 170-6. PMID 21330066 DOI: 10.1016/J.Drugalcdep.2010.12.006  0.686
2011 Boschloo L, Vogelzangs N, Smit JH, van den Brink W, Veltman DJ, Beekman AT, Penninx BW. Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA). Journal of Affective Disorders. 131: 233-42. PMID 21247636 DOI: 10.1016/J.Jad.2010.12.014  0.69
2011 Crunelle CL, Schulz S, de Bruin K, Miller ML, van den Brink W, Booij J. Dose-dependent and sustained effects of varenicline on dopamine D2/3 receptor availability in rats. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 21: 205-10. PMID 21130610 DOI: 10.1016/J.Euroneuro.2010.11.001  0.661
2011 Luijten M, Veltman DJ, van den Brink W, Hester R, Field M, Smits M, Franken IH. Neurobiological substrate of smoking-related attentional bias. Neuroimage. 54: 2374-81. PMID 20932921 DOI: 10.1016/J.Neuroimage.2010.09.064  0.574
2011 Burke SM, van de Giessen E, de Win M, Schilt T, van Herk M, van den Brink W, Booij J. Serotonin and dopamine transporters in relation to neuropsychological functioning, personality traits and mood in young adult healthy subjects. Psychological Medicine. 41: 419-29. PMID 20367893 DOI: 10.1017/S0033291710000486  0.701
2010 Goudriaan AE, de Ruiter MB, van den Brink W, Oosterlaan J, Veltman DJ. Brain activation patterns associated with cue reactivity and craving in abstinent problem gamblers, heavy smokers and healthy controls: an fMRI study. Addiction Biology. 15: 491-503. PMID 20840335 DOI: 10.1111/J.1369-1600.2010.00242.X  0.764
2010 van Holst RJ, van den Brink W, Veltman DJ, Goudriaan AE. Brain imaging studies in pathological gambling. Current Psychiatry Reports. 12: 418-25. PMID 20676945 DOI: 10.1007/S11920-010-0141-7  0.792
2010 Boschloo L, Vogelzangs N, Smit JH, van den Brink W, Veltman DJ, Beekman AT, Penninx BW. The performance of the Alcohol Use Disorder Identification Test (AUDIT) in detecting alcohol abuse and dependence in a population of depressed or anxious persons. Journal of Affective Disorders. 126: 441-6. PMID 20537398 DOI: 10.1016/J.Jad.2010.04.019  0.693
2010 Crunelle CL, Miller ML, Booij J, van den Brink W. The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: 69-79. PMID 19959340 DOI: 10.1016/J.Euroneuro.2009.11.001  0.673
2010 van Holst RJ, van den Brink W, Veltman DJ, Goudriaan AE. Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neuroscience and Biobehavioral Reviews. 34: 87-107. PMID 19632269 DOI: 10.1016/J.Neubiorev.2009.07.007  0.794
2009 Crunelle CL, Miller ML, de Bruin K, van den Brink W, Booij J. Varenicline increases striatal dopamine D(2/3) receptor binding in rats. Addiction Biology. 14: 500-2. PMID 19650815 DOI: 10.1111/J.1369-1600.2009.00168.X  0.656
2009 van de Giessen E, de Win MM, Tanck MW, van den Brink W, Baas F, Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 45-52. PMID 19091889 DOI: 10.2967/Jnumed.108.053652  0.666
2009 Schilt T, Goudriaan AE, Koeter MW, van den Brink W, Schmand B. Decision making as a predictor of first ecstasy use: a prospective study. Psychopharmacology. 203: 519-27. PMID 19020868 DOI: 10.1007/S00213-008-1398-Y  0.657
2009 de Ruiter MB, Veltman DJ, Goudriaan AE, Oosterlaan J, Sjoerds Z, van den Brink W. Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 1027-38. PMID 18830241 DOI: 10.1038/Npp.2008.175  0.798
2009 Zijlstra F, Veltman DJ, Booij J, van den Brink W, Franken IH. Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug and Alcohol Dependence. 99: 183-92. PMID 18823721 DOI: 10.1016/J.Drugalcdep.2008.07.012  0.679
2008 de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain : a Journal of Neurology. 131: 2936-45. PMID 18842607 DOI: 10.1093/Brain/Awn255  0.625
2008 de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, Ramsey NF, Heeten GJ, van den Brink W. Neurotoxic effects of ecstasy on the thalamus. The British Journal of Psychiatry : the Journal of Mental Science. 193: 289-96. PMID 18827290 DOI: 10.1192/Bjp.Bp.106.035089  0.613
2008 Zijlstra F, Booij J, van den Brink W, Franken IH. Striatal dopamine D2 receptor binding and dopamine release during cue-elicited craving in recently abstinent opiate-dependent males. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 18: 262-70. PMID 18077142 DOI: 10.1016/J.Euroneuro.2007.11.002  0.456
2008 Goudriaan AE, Oosterlaan J, De Beurs E, Van Den Brink W. The role of self-reported impulsivity and reward sensitivity versus neurocognitive measures of disinhibition and decision-making in the prediction of relapse in pathological gamblers. Psychological Medicine. 38: 41-50. PMID 17498322 DOI: 10.1017/S0033291707000694  0.674
2007 de Win MM, Reneman L, Jager G, Vlieger EJ, Olabarriaga SD, Lavini C, Bisschops I, Majoie CB, Booij J, den Heeten GJ, van den Brink W. A prospective cohort study on sustained effects of low-dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 458-70. PMID 17077812 DOI: 10.1038/Sj.Npp.1301225  0.644
2006 Reneman L, Schilt T, de Win MM, Booij J, Schmand B, van den Brink W, Bakker O. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. Journal of Psychopharmacology (Oxford, England). 20: 389-99. PMID 16574713 DOI: 10.1177/0269881106063266  0.613
2006 Goudriaan AE, Oosterlaan J, de Beurs E, van den Brink W. Psychophysiological determinants and concomitants of deficient decision making in pathological gamblers. Drug and Alcohol Dependence. 84: 231-9. PMID 16574343 DOI: 10.1016/J.Drugalcdep.2006.02.007  0.658
2006 Goudriaan AE, Oosterlaan J, de Beurs E, van den Brink W. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction (Abingdon, England). 101: 534-47. PMID 16548933 DOI: 10.1111/J.1360-0443.2006.01380.X  0.701
2006 de Win MM, Schilt T, Reneman L, Vervaeke H, Jager G, Dijkink S, Booij J, van den Brink W. Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study. Journal of Psychopharmacology (Oxford, England). 20: 226-35. PMID 16510480 DOI: 10.1177/0269881106063275  0.615
2006 Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. Journal of Psychopharmacology (Oxford, England). 20: 164-75. PMID 16510475 DOI: 10.1177/0269881106061515  0.614
2005 De Win MM, Jager G, Vervaeke HK, Schilt T, Reneman L, Booij J, Verhulst FC, Den Heeten GJ, Ramsey NF, Korf DJ, Van den Brink W. The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. International Journal of Methods in Psychiatric Research. 14: 167-85. PMID 16395871 DOI: 10.1002/Mpr.6  0.633
2005 Franken IH, Booij J, van den Brink W. The role of dopamine in human addiction: from reward to motivated attention. European Journal of Pharmacology. 526: 199-206. PMID 16256105 DOI: 10.1016/J.Ejphar.2005.09.025  0.445
2005 Goudriaan AE, Oosterlaan J, de Beurs E, van den Brink W. Decision making in pathological gambling: a comparison between pathological gamblers, alcohol dependents, persons with Tourette syndrome, and normal controls. Brain Research. Cognitive Brain Research. 23: 137-51. PMID 15795140 DOI: 10.1016/J.Cogbrainres.2005.01.017  0.663
2005 de Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 996-1005. PMID 15770240 DOI: 10.1038/Sj.Npp.1300683  0.591
2004 Goudriaan AE, Oosterlaan J, de Beurs E, Van den Brink W. Pathological gambling: a comprehensive review of biobehavioral findings. Neuroscience and Biobehavioral Reviews. 28: 123-41. PMID 15172761 DOI: 10.1016/J.Neubiorev.2004.03.001  0.679
2004 de Win MM, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W. Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. Psychopharmacology. 173: 376-82. PMID 14726997 DOI: 10.1007/S00213-003-1723-4  0.623
2002 Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Gunning B, den Heeten GJ, van Den Brink W. Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study--preliminary report. Psychopharmacology. 159: 335-40. PMID 11862367 DOI: 10.1007/S00213-001-0930-0  0.623
2001 Reneman L, Booij J, Majoie CB, Van Den Brink W, Den Heeten GJ. Investigating the potential neurotoxicity of Ecstasy (MDMA): an imaging approach. Human Psychopharmacology. 16: 579-588. PMID 12404537 DOI: 10.1002/Hup.347  0.614
2001 Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet. 358: 1864-9. PMID 11741626 DOI: 10.1016/S0140-6736(01)06888-X  0.612
2001 Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Archives of General Psychiatry. 58: 901-6. PMID 11576026 DOI: 10.1001/Archpsyc.58.10.901  0.598
2000 Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology. 148: 322-4. PMID 10755746 DOI: 10.1007/S002130050057  0.602
1994 Ormel J, van den Brink W, van der Meer K, Jenner J, Giel R. [Prevalence, indication and course of depression in family practice]. Nederlands Tijdschrift Voor Geneeskunde. 138: 123-6. PMID 8295637  0.453
1993 Ormel J, Von Korff M, Van den Brink W, Katon W, Brilman E, Oldehinkel T. Depression, anxiety, and social disability show synchrony of change in primary care patients. American Journal of Public Health. 83: 385-90. PMID 8438977 DOI: 10.2105/Ajph.83.3.385  0.751
1992 Wiznitzer M, Verhulst FC, van den Brink W, Koeter M, van der Ende J, Giel R, Koot HM. Detecting psychopathology in young adults: the Young Adult Self Report, the General Health Questionnaire and the Symptom Checklist as screening instruments. Acta Psychiatrica Scandinavica. 86: 32-7. PMID 1414396 DOI: 10.1111/J.1600-0447.1992.Tb03221.X  0.47
1990 Ormel J, Van Den Brink W, Koeter MW, Giel R, Van Der Meer K, Van De Willige G, Wilmink FW. Recognition, management and outcome of psychological disorders in primary care: a naturalistic follow-up study. Psychological Medicine. 20: 909-23. PMID 2284397  0.504
1989 van den Brink W, Koeter MW, Ormel J, Dijkstra W, Giel R, Slooff CJ, Wohlfarth TD. Psychiatric diagnosis in an outpatient population. A comparative study of PSE-Catego and DSM-III. Archives of General Psychiatry. 46: 369-72. PMID 2930333 DOI: 10.1001/archpsyc.1989.01810040075011  0.502
1989 Ormel J, Koeter MW, van den Brink W, Giel R. Concurrent validity of GHQ-28 and PSE as measures of change. Psychological Medicine. 19: 1007-13. PMID 2594877  0.478
Low-probability matches (unlikely to be authored by this person)
2005 Dom G, Sabbe B, Hulstijn W, van den Brink W. Substance use disorders and the orbitofrontal cortex: systematic review of behavioural decision-making and neuroimaging studies. The British Journal of Psychiatry : the Journal of Mental Science. 187: 209-20. PMID 16135857 DOI: 10.1192/bjp.187.3.209  0.244
2004 Schadé A, Marquenie LA, Van Balkom AJ, Koeter MW, De Beurs E, Van Den Brink W, Van Dyck R. Alcohol-dependent patients with comorbid phobic disorders: a comparison between comorbid patients, pure alcohol-dependent and pure phobic patients. Alcohol and Alcoholism (Oxford, Oxfordshire). 39: 241-6. PMID 15082462 DOI: 10.1093/alcalc/agh039  0.243
2005 van den Bosch LM, Koeter MW, Stijnen T, Verheul R, van den Brink W. Sustained efficacy of dialectical behaviour therapy for borderline personality disorder. Behaviour Research and Therapy. 43: 1231-41. PMID 16005708 DOI: 10.1016/j.brat.2004.09.008  0.242
2010 van Zaane J, van den Brink W, Draisma S, Smit JH, Nolen WA. The effect of moderate and excessive alcohol use on the course and outcome of patients with bipolar disorders: a prospective cohort study. The Journal of Clinical Psychiatry. 71: 885-93. PMID 20122372 DOI: 10.4088/Jcp.09M05079Gry  0.241
2008 Schadé A, Marquenie LA, van Balkom AJ, Koeter MM, van den Brink W, van Dyck R. [The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomised controlled trial]. Tijdschrift Voor Psychiatrie. 50: 137-48. PMID 18324601  0.241
2006 Marquenie LA, Schadé A, Van Balkom AJ, Koeter M, Frenken S, van den Brink W, van Dyck R. Comorbid phobic disorders do not influence outcome of alcohol dependence treatment. Results of a naturalistic follow-up study. Alcohol and Alcoholism (Oxford, Oxfordshire). 41: 168-73. PMID 16352656 DOI: 10.1093/alcalc/agh252  0.24
2005 Schadé A, Marquenie LA, van Balkom AJ, Koeter MW, de Beurs E, van den Brink W, van Dyck R. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcoholism, Clinical and Experimental Research. 29: 794-800. PMID 15897725 DOI: 10.1097/01.ALC.0000163511.24583.33  0.237
1999 Verheul R, van den Brink W, Koeter MW, Hartgers C. Antisocial alcoholic patients show as much improvement at 14-month follow-up as non-antisocial alcoholic patients. The American Journal On Addictions. 8: 24-33. PMID 10189512 DOI: 10.1080/105504999306054  0.236
2003 Schadé A, Marquenie LA, Van Balkom AJ, De Beurs E, Van Dyck R, Van Den Brink W. Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse? Alcohol and Alcoholism (Oxford, Oxfordshire). 38: 255-62. PMID 12711661 DOI: 10.1093/alcalc/agg062  0.235
2004 de Bruijn C, Korzec A, Koerselman F, van Den Brink W. Craving and withdrawal as core symptoms of alcohol dependence. The Journal of Nervous and Mental Disease. 192: 494-502. PMID 15232320 DOI: 10.1097/01.nmd.0000131912.71344.e4  0.234
2007 Schadé A, Marquenie LA, van Balkom AJ, Koeter MW, de Beurs E, van Dyck R, van den Brink W. Anxiety disorders: treatable regardless of the severity of comorbid alcohol dependence. European Addiction Research. 13: 109-15. PMID 17356283 DOI: 10.1159/000097941  0.234
2020 Temmingh HS, van den Brink W, Howells F, Sibeko G, Stein DJ. Methamphetamine use and antipsychotic-related extrapyramidal side-effects in patients with psychotic disorders. Journal of Dual Diagnosis. 1-10. PMID 31984872 DOI: 10.1080/15504263.2020.1714099  0.232
2014 van Zaane J, van de Ven PM, Draisma S, Smit JH, Nolen WA, van den Brink W. Effect of alcohol use on the course of bipolar disorder: one-year follow-up study using the daily prospective Life Chart method. Bipolar Disorders. 16: 400-9. PMID 24673879 DOI: 10.1111/Bdi.12191  0.231
2016 Maraz A, Andó B, Rigó P, Harmatta J, Takách G, Zalka Z, Boncz I, Lackó Z, Urbán R, van den Brink W, Demetrovics Z. The two-faceted nature of impulsivity in patients with borderline personality disorder and substance use disorder. Drug and Alcohol Dependence. PMID 27107850 DOI: 10.1016/j.drugalcdep.2016.03.015  0.23
2012 Dekker N, Koeter M, Van Den Brink W. Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. International Journal of Methods in Psychiatric Research. 21: 286-300. PMID 22961922 DOI: 10.1002/mpr.1362  0.229
2012 van Amsterdam JG, Brunt TM, McMaster MT, Niesink R, van Noorden MS, van den Brink W. [Cognitive impairment due to intensive use and overdoses of gammahydroxybutyric acid (GHB)]. Tijdschrift Voor Psychiatrie. 54: 1001-10. PMID 23250641  0.227
2004 Roozen HG, Boulogne JJ, van Tulder MW, van den Brink W, De Jong CA, Kerkhof AJ. A systematic review of the effectiveness of the community reinforcement approach in alcohol, cocaine and opioid addiction. Drug and Alcohol Dependence. 74: 1-13. PMID 15072802 DOI: 10.1016/J.DRUGALCDEP.2003.12.006  0.225
2005 Franken IH, Hendriks VM, Stam CJ, Van den Brink W. A role for dopamine in the processing of drug cues in heroin dependent patients. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14: 503-8. PMID 15589390 DOI: 10.1016/j.euroneuro.2004.02.004  0.225
1993 DeJong CA, van den Brink W, Harteveld FM, van der Wielen EG. Personality disorders in alcoholics and drug addicts. Comprehensive Psychiatry. 34: 87-94. PMID 8387417 DOI: 10.1016/0010-440X(93)90052-6  0.225
2014 Roozen HG, Strietman M, Wiersema H, Meyers RJ, Lewinsohn PM, Feij JA, Greeven PG, Vingerhoets AJ, van den Brink W. Engagement of pleasant activities in patients with substance use disorders: a correlational study. Substance Abuse. 35: 254-61. PMID 24417592 DOI: 10.1080/08897077.2013.873760  0.225
1999 Verheul R, van den Brink W, Geerlings P. A three-pathway psychobiological model of craving for alcohol. Alcohol and Alcoholism (Oxford, Oxfordshire). 34: 197-222. PMID 10344781 DOI: 10.1093/ALCALC/34.2.197  0.224
2016 Tuithof M, Ten Have M, van den Brink W, Vollebergh W, de Graaf R. Treatment Seeking for Alcohol Use Disorders: Treatment Gap or Adequate Self-Selection. European Addiction Research. 22: 277-285. PMID 27287873 DOI: 10.1159/000446822  0.223
2018 van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, et al. Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level. Addiction Biology. 23: 969-986. PMID 30043457 DOI: 10.1111/Adb.12645  0.222
2020 López-Pelayo H, Zuluaga P, Caballeria E, Van den Brink W, Mann K, Gual A. Safety of nalmefene for the treatment of alcohol use disorder: an update. Expert Opinion On Drug Safety. 19: 9-17. PMID 31868031 DOI: 10.1080/14740338.2020.1707802  0.22
2018 Agabio R, Sinclair JM, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Heydtman M, Jaury P, Lingford-Hughes AR, Morley KC, ... ... van den Brink W, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. The Lancet. Psychiatry. PMID 30413394 DOI: 10.1016/S2215-0366(18)30303-1  0.219
1997 Ustün B, Compton W, Mager D, Babor T, Baiyewu O, Chatterji S, Cottler L, Göğüş A, Mavreas V, Peters L, Pull C, Saunders J, Smeets R, Stipec MR, Vrasti R, ... ... Van den Brink W, et al. WHO Study on the reliability and validity of the alcohol and drug use disorder instruments: overview of methods and results. Drug and Alcohol Dependence. 47: 161-9. PMID 9306042 DOI: 10.1016/S0376-8716(97)00087-2  0.219
2007 Marquenie LA, Schadé A, van Balkom AJ, Comijs HC, de Graaf R, Vollebergh W, van Dyck R, van den Brink W. Origin of the comorbidity of anxiety disorders and alcohol dependence: findings of a general population study. European Addiction Research. 13: 39-49. PMID 17172778 DOI: 10.1159/000095814  0.218
2014 Tuithof M, Ten Have M, van den Brink W, Vollebergh W, de Graaf R. The relationship between excessive alcohol consumption and alcohol use disorders according to DSM-IV and DSM-5. Alcoholism, Clinical and Experimental Research. 38: 249-56. PMID 24033529 DOI: 10.1111/Acer.12248  0.218
2018 Raposo Pereira F, McMaster MTB, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Effect of GHB-use and GHB-induced comas on dorsolateral prefrontal cortex functioning in humans. Neuroimage. Clinical. 20: 923-930. PMID 30308378 DOI: 10.1016/j.nicl.2018.09.022  0.216
2003 Vreugdenhil C, Van Den Brink W, Wouters LF, Doreleijers TA. Substance use, substance use disorders, and comorbidity patterns in a representative sample of incarcerated male Dutch adolescents. The Journal of Nervous and Mental Disease. 191: 372-8. PMID 12826918 DOI: 10.1097/01.NMD.0000071585.09816.F4  0.216
2009 Ooteman W, Naassila M, Koeter MW, Verheul R, Schippers GM, Houchi H, Daoust M, van den Brink W. Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addiction Biology. 14: 328-37. PMID 19523047 DOI: 10.1111/j.1369-1600.2009.00159.x  0.216
2006 de Bruijn C, van den Brink W, de Graaf R, Vollebergh WA. The three year course of alcohol use disorders in the general population: DSM-IV, ICD-10 and the Craving Withdrawal Model. Addiction (Abingdon, England). 101: 385-92. PMID 16499511 DOI: 10.1111/j.1360-0443.2006.01327.x  0.215
2022 van Amsterdam J, Blanken P, Spijkerman R, van den Brink W, Hendriks V. The Added Value of Pharmacotherapy to Cognitive Behavior Therapy And Vice Versa in the Treatment of Alcohol Use Disorders: A Systematic Review. Alcohol and Alcoholism (Oxford, Oxfordshire). PMID 36085572 DOI: 10.1093/alcalc/agac043  0.214
2013 Brunt TM, Koeter MW, Hertoghs N, van Noorden MS, van den Brink W. Sociodemographic and substance use characteristics of γ hydroxybutyrate (GHB) dependent inpatients and associations with dependence severity. Drug and Alcohol Dependence. 131: 316-9. PMID 23332440 DOI: 10.1016/j.drugalcdep.2012.12.023  0.213
2008 Jager G, de Win MM, van der Tweel I, Schilt T, Kahn RS, van den Brink W, van Ree JM, Ramsey NF. Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 33: 247-58. PMID 17460617 DOI: 10.1038/Sj.Npp.1301415  0.213
2015 Nutt DJ, Rehm J, van den Brink W, Gorwood P, Buchsbaum MS. Progress in mind: focus on alcohol use disorders, an elsevier resource centre. Psychiatry Research. 226: 513-4. PMID 25724487 DOI: 10.1016/J.Psychres.2015.01.013  0.211
2013 Tuithof M, Ten Have M, van den Brink W, Vollebergh W, de Graaf R. Predicting persistency of DSM-5 alcohol use disorder and examining drinking patterns of recently remitted individuals: a prospective general population study. Addiction (Abingdon, England). 108: 2091-9. PMID 23889861 DOI: 10.1111/Add.12309  0.21
2015 Ortal S, Johan F, Itai B, Nir Y, Iliyan I, van den Brink W. The role of different aspects of impulsivity as independent risk factors for substance use disorders in patients with ADHD: A review. Current Drug Abuse Reviews. PMID 26373850  0.21
2021 van Amsterdam J, Brunt TM, Pierce M, van den Brink W. Hard Boiled: Alcohol Use as a Risk Factor for MDMA-Induced Hyperthermia: a Systematic Review. Neurotoxicity Research. PMID 34554408 DOI: 10.1007/s12640-021-00416-z  0.209
2004 de Bruijn H, Korzec A, Arndt T, van den Brink W. The discriminant validity of alcohol use disorder in well-functioning men with hazardous alcohol use. European Addiction Research. 9: 182-7. PMID 12970587 DOI: 10.1159/000072224  0.209
2014 Brunt TM, van Amsterdam JG, van den Brink W. GHB, GBL and 1,4-BD addiction. Current Pharmaceutical Design. 20: 4076-85. PMID 24001290 DOI: 10.2174/13816128113199990624  0.208
2003 Rinne T, de Kloet ER, Wouters L, Goekoop JG, de Rijk RH, van den Brink W. Fluvoxamine reduces responsiveness of HPA axis in adult female BPD patients with a history of sustained childhood abuse. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 126-32. PMID 12496948 DOI: 10.1038/sj.npp.1300003  0.208
2011 Nuijten M, Blanken P, van den Brink W, Hendriks V. Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): new pharmacological treatment options for crack-cocaine dependence in the Netherlands. Bmc Psychiatry. 11: 135. PMID 21854580 DOI: 10.1186/1471-244X-11-135  0.208
2005 de Bruijn C, van den Brink W, de Graaf R, Vollebergh WA. Alcohol abuse and dependence criteria as predictors of a chronic course of alcohol use disorders in the general population. Alcohol and Alcoholism (Oxford, Oxfordshire). 40: 441-6. PMID 16009673 DOI: 10.1093/alcalc/agh183  0.207
2017 Schipper R, Dekker M, de Haan L, van den Brink W. Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. Journal of Psychopharmacology (Oxford, England). 269881117735684. PMID 29039260 DOI: 10.1177/0269881117735684  0.207
2012 van Zaane J, van den Berg B, Draisma S, Nolen WA, van den Brink W. Screening for bipolar disorders in patients with alcohol or substance use disorders: performance of the mood disorder questionnaire. Drug and Alcohol Dependence. 124: 235-41. PMID 22341144 DOI: 10.1016/J.Drugalcdep.2012.01.018  0.207
2003 van den Brink W, van Ree JM. Pharmacological treatments for heroin and cocaine addiction. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 13: 476-87. PMID 14636964 DOI: 10.1016/j.euroneuro.2003.08.008  0.206
2019 Raposo Pereira F, Zhutovsky P, Mcmaster MTB, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Recreational use of GHB is associated with alterations of resting state functional connectivity of the central executive and default mode networks. Human Brain Mapping. PMID 30720906 DOI: 10.1002/hbm.24532  0.206
2023 van Amsterdam J, van den Brink W. Combined use of cocaine and alcohol: A violent cocktail? A systematic review. Journal of Forensic and Legal Medicine. 100: 102597. PMID 37832170 DOI: 10.1016/j.jflm.2023.102597  0.206
2008 Schilt T, de Win MM, Jager G, Koeter MW, Ramsey NF, Schmand B, van den Brink W. Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users. Psychological Medicine. 38: 1309-17. PMID 17988417 DOI: 10.1017/S0033291707002140  0.205
2002 Langeland W, Draijer N, van den Brink W. Trauma and dissociation in treatment-seeking alcoholics: towards a resolution of inconsistent findings. Comprehensive Psychiatry. 43: 195-203. PMID 11994837 DOI: 10.1053/COMP.2002.32350  0.204
2013 Mann K, Bladström A, Torup L, Gual A, van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biological Psychiatry. 73: 706-13. PMID 23237314 DOI: 10.1016/j.biopsych.2012.10.020  0.203
2007 Jager G, Van Hell HH, De Win MM, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Effects of frequent cannabis use on hippocampal activity during an associative memory task. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 17: 289-97. PMID 17137758 DOI: 10.1016/J.Euroneuro.2006.10.003  0.203
2005 de Bruijn C, van den Brink W, de Graaf R, Vollebergh WA. The craving withdrawal model for alcoholism: towards the DSM-V. Improving the discriminant validity of alcohol use disorder diagnosis. Alcohol and Alcoholism (Oxford, Oxfordshire). 40: 314-22. PMID 15883129 DOI: 10.1093/ALCALC/AGH166  0.203
2022 van Amsterdam J, van den Brink W. Smoking As an Outcome Moderator In the Treatment of Alcohol Use Disorders. Alcohol and Alcoholism (Oxford, Oxfordshire). PMID 35589093 DOI: 10.1093/alcalc/agac027  0.203
2014 van Amsterdam J, Brunt T, Pennings E, van den Brink W. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regulatory Toxicology and Pharmacology : Rtp. 70: 507-13. PMID 25204614 DOI: 10.1016/j.yrtph.2014.08.014  0.202
2013 Matthys F, Joostens P, van den Brink W, Sabbe B. [Summary of the practice guideline for the diagnosis and treatment of ADHD in adolescents and adults with addictions]. Nederlands Tijdschrift Voor Geneeskunde. 157: A6025. PMID 23759179  0.201
2018 Morley KC, Baillie A, van den Brink W, Chitty K, Brady K, Back S, Sutherland G, Seth D, Leggio L, Haber PS. Rationale for N-acetyl cysteine in the treatment of alcohol use disorder in patients with liver disease. Expert Opinion On Investigational Drugs. PMID 30019966 DOI: 10.1080/13543784.2018.1501471  0.201
2014 van Emmerik-van Oortmerssen K, van de Glind G, Koeter MW, Allsop S, Auriacombe M, Barta C, Bu ET, Burren Y, Carpentier PJ, Carruthers S, Casas M, Demetrovics Z, Dom G, Faraone SV, Fatseas M, ... ... van den Brink W, et al. Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the IASP study. Addiction (Abingdon, England). 109: 262-72. PMID 24118292 DOI: 10.1111/Add.12370  0.201
2019 Blanken P, Nuijten M, van den Brink W, Hendriks VM. Clinical effects beyond cocaine use of sustained-release dexamphetamine for the treatment of cocaine dependent patients with comorbid opioid dependence: secondary analysis of a double-blind, placebo-controlled randomized trial. Addiction (Abingdon, England). PMID 31908066 DOI: 10.1111/add.14874  0.201
2012 van den Brink W, Schippers GM. [Staging and profiling in addication]. Tijdschrift Voor Psychiatrie. 54: 941-8. PMID 23138621  0.2
2008 van Nimwegen LJ, de Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 53: 400-5. PMID 18616861 DOI: 10.1177/070674370805300610  0.199
2002 Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. The American Journal of Psychiatry. 159: 2048-54. PMID 12450955 DOI: 10.1176/appi.ajp.159.12.2048  0.199
2017 Beraha E, Bodewits P, van den Brink W, Wiers R. Speaking fluently with baclofen? Bmj Case Reports. 2017. PMID 28495786 DOI: 10.1136/bcr-2016-218714  0.199
2013 van Amsterdam J, van den Brink W. Reduced-risk drinking as a viable treatment goal in problematic alcohol use and alcohol dependence. Journal of Psychopharmacology (Oxford, England). 27: 987-97. PMID 23824247 DOI: 10.1177/0269881113495320  0.199
2013 Gual A, He Y, Torup L, van den Brink W, Mann K. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 1432-42. PMID 23562264 DOI: 10.1016/j.euroneuro.2013.02.006  0.199
2020 Icick R, Moggi F, Slobodin O, Dom G, Mathys F, van den Brink W, Levin FR, Blankers M, Kaye S, Demetrovics Z, van den Glind G, Velez-Pastrana MC, Schellekens ASA. Attention Deficit/Hyperactivity Disorder and Global Severity Profiles in Treatment-Seeking Patients with Substance Use Disorders. European Addiction Research. 1-10. PMID 32570249 DOI: 10.1159/000508546  0.198
2015 Maraz A, van den Brink W, Demetrovics Z. Prevalence and construct validity of compulsive buying disorder in shopping mall visitors. Psychiatry Research. 228: 918-24. PMID 26027442 DOI: 10.1016/j.psychres.2015.04.012  0.198
2014 Tuithof M, ten Have M, van den Brink W, Vollebergh W, de Graaf R. Alcohol consumption and symptoms as predictors for relapse of DSM-5 alcohol use disorder. Drug and Alcohol Dependence. 140: 85-91. PMID 24793368 DOI: 10.1016/J.Drugalcdep.2014.03.035  0.197
2020 Sánchez-García NC, González RA, Ramos-Quiroga JA, van den Brink W, Luderer M, Blankers M, Grau-Lopez L, Levin FR, Kaye S, Demetrovics Z, van de Glind G, Schellekens A, Vélez-Pastrana MC. Attention Deficit Hyperactivity Disorder Increases Nicotine Addiction Severity in Adults Seeking Treatment for Substance Use Disorders: The Role of Personality Disorders. European Addiction Research. 1-10. PMID 32564016 DOI: 10.1159/000508545  0.197
2014 Kronenberg LM, Slager-Visscher K, Goossens PJ, van den Brink W, van Achterberg T. Everyday life consequences of substance use in adult patients with a substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD): a patient's perspective. Bmc Psychiatry. 14: 264. PMID 25234344 DOI: 10.1186/s12888-014-0264-1  0.197
2014 van der Meer FJ, Meijer JH, Meijer CJ, van den Brink W, Velthorst E. Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls. Psychological Medicine. 44: 1901-11. PMID 24267407 DOI: 10.1017/S0033291713002626  0.197
2014 van de Glind G, Konstenius M, Koeter MW, van Emmerik-van Oortmerssen K, Carpentier PJ, Kaye S, Degenhardt L, Skutle A, Franck J, Bu ET, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, ... ... van den Brink W, et al. Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug and Alcohol Dependence. 134: 158-66. PMID 24156882 DOI: 10.1016/J.Drugalcdep.2013.09.026  0.197
2012 van den Brink W. Evidence-based pharmacological treatment of substance use disorders and pathological gambling. Current Drug Abuse Reviews. 5: 3-31. PMID 22126708  0.196
2011 van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. The Dutch Cannabis Dependence (CanDep) study on the course of frequent cannabis use and dependence: objectives, methods and sample characteristics. International Journal of Methods in Psychiatric Research. 20: 169-81. PMID 21815231 DOI: 10.1002/mpr.345  0.196
2004 Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology. 178: 167-73. PMID 15322728 DOI: 10.1007/s00213-004-1991-7  0.196
2013 van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug and Alcohol Dependence. 133: 352-9. PMID 23886472 DOI: 10.1016/j.drugalcdep.2013.06.009  0.196
2024 Guiraud J, Spanagel R, van den Brink W. Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy. International Review of Neurobiology. 175: 187-239. PMID 38555116 DOI: 10.1016/bs.irn.2024.03.005  0.195
2020 González RA, Vélez-Pastrana MC, Blankers M, Bäcker A, Konstenius M, Holtmann M, Levin FR, Noack M, Kaye S, Demetrovics Z, van den Glind G, van den Brink W, Schellekens A. Onset and Severity of Early Disruptive Behavioral Disorders in Treatment-Seeking Substance Use Disorder Patients with and without Attention-Deficit/Hyperactivity Disorder. European Addiction Research. 1-12. PMID 32594079 DOI: 10.1159/000508653  0.195
2021 Guiraud J, Addolorato G, Aubin HJ, Batel P, de Bejczy A, Caputo F, Goudriaan AE, Gual A, Lesch O, Maremmani I, Perney P, Poulnais R, Raffaillac Q, Soderpalm B, Spanagel R, ... ... van den Brink W, et al. Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 52: 18-30. PMID 34237655 DOI: 10.1016/j.euroneuro.2021.06.003  0.195
2009 Oudejans SC, Schippers GM, Merkx MJ, Schramade MH, Koeter MW, van den Brink W. Feasibility and validity of low-budget telephonic follow-up interviews in routine outcome monitoring of substance abuse treatment. Addiction (Abingdon, England). 104: 1138-46. PMID 19563559 DOI: 10.1111/j.1360-0443.2009.02593.x  0.194
2006 Ooteman W, Koeter MW, Vserheul R, Schippers GM, van den Brink W. Measuring craving: an attempt to connect subjective craving with cue reactivity. Alcoholism, Clinical and Experimental Research. 30: 57-69. PMID 16433732 DOI: 10.1111/j.1530-0277.2006.00019.x  0.194
2004 Franken IH, Stam CJ, Hendriks VM, van den Brink W. Electroencephalographic power and coherence analyses suggest altered brain function in abstinent male heroin-dependent patients. Neuropsychobiology. 49: 105-10. PMID 14981343 DOI: 10.1159/000076419  0.194
2007 Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 17: 558-66. PMID 17379484 DOI: 10.1016/j.euroneuro.2007.02.012  0.193
2006 Marissen MA, Franken IH, Waters AJ, Blanken P, van den Brink W, Hendriks VM. Attentional bias predicts heroin relapse following treatment. Addiction (Abingdon, England). 101: 1306-12. PMID 16911730 DOI: 10.1111/j.1360-0443.2006.01498.x  0.193
2014 van den Brink W. [Addictive behaviours from DSM-IV to DSM-5]. Tijdschrift Voor Psychiatrie. 56: 206-10. PMID 24643833  0.192
2022 López-Toro E, Wolf CJH, González RA, van den Brink W, Schellekens A, Vélez-Pastrana MC. Network Analysis of DSM Symptoms of Substance Use Disorders and Frequently Co-Occurring Mental Disorders in Patients with Substance Use Disorder Who Seek Treatment. Journal of Clinical Medicine. 11. PMID 35629008 DOI: 10.3390/jcm11102883  0.192
2006 Jager G, Kahn RS, Van Den Brink W, Van Ree JM, Ramsey NF. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology. 185: 358-68. PMID 16521034 DOI: 10.1007/s00213-005-0298-7  0.192
2004 Langeland W, Draijer N, van den Brink W. Psychiatric comorbidity in treatment-seeking alcoholics: the role of childhood trauma and perceived parental dysfunction. Alcoholism, Clinical and Experimental Research. 28: 441-7. PMID 15084902 DOI: 10.1097/01.ALC.0000117831.17383.72  0.191
2012 Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W. Craving and illicit heroin use among patients in heroin-assisted treatment. Drug and Alcohol Dependence. 120: 74-80. PMID 21782351 DOI: 10.1016/j.drugalcdep.2011.06.025  0.191
2006 Roozen HG, de Waart R, van der Windt DA, van den Brink W, de Jong CA, Kerkhof AJ. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 311-23. PMID 16361086 DOI: 10.1016/j.euroneuro.2005.11.001  0.191
2006 Ooteman W, Koeter M, Verheul R, Schippers G, Van den Brink W. Development and validation of the Amsterdam Motives for Drinking Scale (AMDS): an attempt to distinguish relief and reward drinkers. Alcohol and Alcoholism (Oxford, Oxfordshire). 41: 284-92. PMID 16540493 DOI: 10.1093/alcalc/agl012  0.19
2012 Tuithof M, ten Have M, van den Brink W, Vollebergh W, de Graaf R. The role of conduct disorder in the association between ADHD and alcohol use (disorder). Results from the Netherlands Mental Health Survey and Incidence Study-2. Drug and Alcohol Dependence. 123: 115-21. PMID 22118715 DOI: 10.1016/J.Drugalcdep.2011.10.030  0.19
2009 Sizoo B, van den Brink W, Gorissen van Eenige M, van der Gaag RJ. Personality characteristics of adults with autism spectrum disorders or attention deficit hyperactivity disorder with and without substance use disorders. The Journal of Nervous and Mental Disease. 197: 450-4. PMID 19525746 DOI: 10.1097/NMD.0b013e3181a61dd0  0.189
2016 Mann K, Torup L, Sørensen P, Gual A, Swift R, Walker B, van den Brink W. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 27842940 DOI: 10.1016/j.euroneuro.2016.10.008  0.189
2002 van den Bosch LM, Verheul R, van den Brink W. Substance abuse in borderline personality disorder: clinical and etiological correlates. Journal of Personality Disorders. 15: 416-24. PMID 11723876 DOI: 10.1521/PEDI.15.5.416.19201  0.189
2002 Rinne T, de Kloet ER, Wouters L, Goekoop JG, DeRijk RH, van den Brink W. Hyperresponsiveness of hypothalamic-pituitary-adrenal axis to combined dexamethasone/corticotropin-releasing hormone challenge in female borderline personality disorder subjects with a history of sustained childhood abuse. Biological Psychiatry. 52: 1102-12. PMID 12460693 DOI: 10.1016/S0006-3223(02)01395-1  0.188
2021 Özgen H, Spijkerman R, Noack M, Holtmann M, Schellekens A, Dalsgaard S, van den Brink W, Hendriks V. Treatment of Adolescents with Concurrent Substance Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review. Journal of Clinical Medicine. 10. PMID 34501355 DOI: 10.3390/jcm10173908  0.188
2007 Jager G, de Win MM, Vervaeke HK, Schilt T, Kahn RS, van den Brink W, van Ree JM, Ramsey NF. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology. 193: 403-14. PMID 17476480 DOI: 10.1007/S00213-007-0792-1  0.188
2015 Kronenberg LM, Goossens PJ, van Busschbach J, van Achterberg T, van den Brink W. Coping styles in substance use disorder (SUD) patients with and without co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD). Bmc Psychiatry. 15: 159. PMID 26169586 DOI: 10.1186/s12888-015-0530-x  0.187
2013 van den Brink W, Aubin HJ, Bladström A, Torup L, Gual A, Mann K. Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: results from a subgroup analysis of two randomized controlled 6-month studies. Alcohol and Alcoholism (Oxford, Oxfordshire). 48: 570-8. PMID 23873853 DOI: 10.1093/alcalc/agt061  0.187
2012 Kuipers MA, van Poppel MN, van den Brink W, Wingen M, Kunst AE. The association between neighborhood disorder, social cohesion and hazardous alcohol use: a national multilevel study. Drug and Alcohol Dependence. 126: 27-34. PMID 22572208 DOI: 10.1016/j.drugalcdep.2012.04.008  0.187
2013 van Amsterdam J, van den Brink W. The high harm score of alcohol. Time for drug policy to be revisited? Journal of Psychopharmacology (Oxford, England). 27: 248-55. PMID 23325370 DOI: 10.1177/0269881112472559  0.186
2021 Scherrer B, Guiraud J, Addolorato G, Aubin HJ, de Bejczy A, Benyamina A, van den Brink W, Caputo F, Dematteis M, Goudriaan AE, Gual A, Kiefer F, Leggio L, Lesch OM, Maremmani I, et al. Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta-regression analysis to develop an enrichment strategy. Alcoholism, Clinical and Experimental Research. PMID 34418121 DOI: 10.1111/acer.14670  0.185
2010 Schippers GM, Broekman TG, Buchholz A, Koeter MW, van den Brink W. Measurements in the Addictions for Triage and Evaluation (MATE): an instrument based on the World Health Organization family of international classifications. Addiction (Abingdon, England). 105: 862-71. PMID 20331557 DOI: 10.1111/j.1360-0443.2009.02889.x  0.185
2016 Nuijten M, Blanken P, van de Wetering B, Nuijen B, van den Brink W, Hendriks VM. Sustained-release dexamfetamine in the treatment of chronic cocaine-dependent patients on heroin-assisted treatment: a randomised, double-blind, placebo-controlled trial. Lancet (London, England). PMID 27015909 DOI: 10.1016/S0140-6736(16)00205-1  0.185
2021 Yuferov V, Butelman ER, Randesi M, van den Brink W, Blanken P, van Ree JM, Kreek MJ. Association of Serotonin Transporter (SERT) Polymorphisms with Opioid Dependence and Dimensional Aspects of Cocaine Use in a Caucasian Cohort of Opioid Users. Neuropsychiatric Disease and Treatment. 17: 659-670. PMID 33658787 DOI: 10.2147/NDT.S286536  0.185
1999 Verheul R, van den Brink W, Hartgers C. Personality disorders predict relapse in alcoholic patients. Addictive Behaviors. 23: 869-82. PMID 9801722 DOI: 10.1016/S0306-4603(98)00065-3  0.184
2013 van Emmerik-van Oortmerssen K, Vedel E, Koeter MW, de Bruijn K, Dekker JJ, van den Brink W, Schoevers RA. Investigating the efficacy of integrated cognitive behavioral therapy for adult treatment seeking substance use disorder patients with comorbid ADHD: study protocol of a randomized controlled trial. Bmc Psychiatry. 13: 132. PMID 23663651 DOI: 10.1186/1471-244X-13-132  0.184
2015 Young JT, Carruthers S, Kaye S, Allsop S, Gilsenan J, Degenhardt L, van de Glind G, van den Brink W, Preen D. Comorbid attention deficit hyperactivity disorder and substance use disorder complexity and chronicity in treatment-seeking adults. Drug and Alcohol Review. PMID 25790353 DOI: 10.1111/dar.12249  0.184
2015 van Emmerik-van Oortmerssen K, Vedel E, van den Brink W, Schoevers RA. Integrated cognitive behavioral therapy for patients with substance use disorder and comorbid ADHD: two case presentations. Addictive Behaviors. 45: 214-7. PMID 25706067 DOI: 10.1016/J.Addbeh.2015.01.040  0.184
2021 Schulte MHJ, Goudriaan AE, Boendermaker WJ, van den Brink W, Wiers RW. The effect of N-acetylcysteine and working memory training on glutamate concentrations in the dACC and rACC in regular cocaine users - a randomized proof of concept study. Neuroscience Letters. 136146. PMID 34332028 DOI: 10.1016/j.neulet.2021.136146  0.183
2006 Dom G, De Wilde B, Hulstijn W, van den Brink W, Sabbe B. Decision-making deficits in alcohol-dependent patients with and without comorbid personality disorder. Alcoholism, Clinical and Experimental Research. 30: 1670-7. PMID 17010134 DOI: 10.1111/J.1530-0277.2006.00202.X  0.182
2007 Marissen MA, Franken IH, Blanken P, van den Brink W, Hendriks VM. Cue exposure therapy for the treatment of opiate addiction: results of a randomized controlled clinical trial. Psychotherapy and Psychosomatics. 76: 97-105. PMID 17230050 DOI: 10.1159/000097968  0.182
2020 Raposo Pereira F, McMaster MTB, de Vries YAT, van den Brink W, van Wingen GA. Demographic and Clinical Characteristics of Regular GHB-Users with and without GHB-Induced Comas. Substance Use & Misuse. 1-8. PMID 32772606 DOI: 10.1080/10826084.2020.1793368  0.182
2015 Wapp M, van de Glind G, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Skutle A, Bu ET, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, ... ... van den Brink W, et al. Risk Factors for Borderline Personality Disorder in Treatment Seeking Patients with a Substance Use Disorder: An International Multicenter Study. European Addiction Research. 21: 188-94. PMID 25832736 DOI: 10.1159/000371724  0.181
2014 van den Brink W, Sørensen P, Torup L, Mann K, Gual A. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study. Journal of Psychopharmacology (Oxford, England). 28: 733-44. PMID 24671340 DOI: 10.1177/0269881114527362  0.181
2018 de Beaurepaire R, Sinclair JMA, Heydtmann M, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Jaury P, Lingford-Hughes AR, Morley KC, ... ... van den Brink W, et al. The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Frontiers in Psychiatry. 9: 708. PMID 30662411 DOI: 10.3389/Fpsyt.2018.00708  0.181
2017 van Emmerik-van Oortmerssen K, Vedel E, Kramer FJ, Koeter MW, Schoevers RA, van den Brink W. Diagnosing ADHD during active substance use: Feasible or flawed? Drug and Alcohol Dependence. 180: 371-375. PMID 28957778 DOI: 10.1016/J.Drugalcdep.2017.07.039  0.181
2006 Rook EJ, Huitema AD, van den Brink W, Hillebrand MJ, van Ree JM, Beijnen JH. Screening for illicit heroin use in patients in a heroin-assisted treatment program. Journal of Analytical Toxicology. 30: 390-4. PMID 16872571 DOI: 10.1093/Jat/30.6.390  0.181
1998 Verheul R, Hartgers C, Van den Brink W, Koeter MW. The effect of sampling, diagnostic criteria and assessment procedures on the observed prevalence of DSM-III-R personality disorders among treated alcoholics. Journal of Studies On Alcohol. 59: 227-36. PMID 9500311 DOI: 10.15288/JSA.1998.59.227  0.18
2022 Brunt TM, van den Brink W, van Amsterdam J. Mechanisms Involved in the Neurotoxicity and Abuse Liability of Nitrous Oxide: A Narrative Review. International Journal of Molecular Sciences. 23. PMID 36499072 DOI: 10.3390/ijms232314747  0.18
2012 Oudejans SC, Schippers GM, Spits ME, Stollenga M, van den Brink W. [Five years of ROM in substance abuse treatment centres in the Netherlands]. Tijdschrift Voor Psychiatrie. 54: 185-90. PMID 22331542  0.18
2003 Franken IH, Stam CJ, Hendriks VM, van den Brink W. Neurophysiological evidence for abnormal cognitive processing of drug cues in heroin dependence. Psychopharmacology. 170: 205-12. PMID 12898125 DOI: 10.1007/s00213-003-1542-7  0.18
2012 Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender. Psychological Medicine. 42: 1903-11. PMID 22452790 DOI: 10.1017/S0033291712000062  0.18
2005 Rehm J, Room R, van den Brink W, Jacobi F. Alcohol use disorders in EU countries and Norway: an overview of the epidemiology. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 15: 377-88. PMID 15925491 DOI: 10.1016/J.Euroneuro.2005.04.005  0.179
2004 Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcoholism, Clinical and Experimental Research. 28: 1356-61. PMID 15365306 DOI: 10.1097/01.Alc.0000139823.30096.52  0.179
2014 Matthys F, Soyez V, van den Brink W, Joostens P, Tremmery S, Sabbe B. Barriers to implementation of treatment guidelines for ADHD in adults with substance use disorder. Journal of Dual Diagnosis. 10: 130-8. PMID 25392286 DOI: 10.1080/15504263.2014.926691  0.179
2013 van de Glind G, van den Brink W, Koeter MW, Carpentier PJ, van Emmerik-van Oortmerssen K, Kaye S, Skutle A, Bu ET, Franck J, Konstenius M, Moggi F, Dom G, Verspreet S, Demetrovics Z, Kapitány-Fövény M, et al. Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug and Alcohol Dependence. 132: 587-96. PMID 23660242 DOI: 10.1016/J.Drugalcdep.2013.04.010  0.178
2007 Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Archives of General Psychiatry. 64: 728-36. PMID 17548754 DOI: 10.1001/archpsyc.64.6.728  0.178
2008 Vervaeke HK, Benschop A, van den Brink W, Korf DJ. Predicting ecstasy use among young people at risk: a prospective study of initially ecstasy-naive subjects. Journal of Drug Education. 38: 131-46. PMID 18724654  0.177
2013 van Amsterdam J, Pennings E, Brunt T, van den Brink W. Physical harm due to chronic substance use. Regulatory Toxicology and Pharmacology : Rtp. 66: 83-7. PMID 23542091 DOI: 10.1016/j.yrtph.2013.03.007  0.177
2020 Raposo Pereira F, McMaster MTB, Schellekens A, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Effects of Recreational GHB Use and Multiple GHB-Induced Comas on Brain Structure and Impulsivity. Frontiers in Psychiatry. 11: 166. PMID 32300311 DOI: 10.3389/fpsyt.2020.00166  0.177
2000 Wiers RW, Hartgers C, van den Brink W, Gunning WB, Sergeant JA. A confirmatory analysis of the hierarchical structure of positive and negative dose-related alcohol expectancies in alcoholics and the associations with family history of alcoholism. Journal of Studies On Alcohol. 61: 177-86. PMID 10627113  0.177
2008 van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. Journal of Clinical Psychopharmacology. 28: 214-8. PMID 18344733 DOI: 10.1097/Jcp.0B013E318166F520  0.177
2002 De Wildt WA, Schippers GM, Van Den Brink W, Potgieter AS, Deckers F, Bets D. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol and Alcoholism (Oxford, Oxfordshire). 37: 375-82. PMID 12107041 DOI: 10.1093/ALCALC/37.4.375  0.176
2005 Franken IH, Hulstijn KP, Stam CJ, Hendriks VM, van den Brink W. Two new neurophysiological indices of cocaine craving: evoked brain potentials and cue modulated startle reflex. Journal of Psychopharmacology (Oxford, England). 18: 544-52. PMID 15582921 DOI: 10.1177/0269881104047282  0.176
2018 Pierce M, Sutterland A, Beraha EM, Morley K, van den Brink W. Efficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. PMID 29934090 DOI: 10.1016/j.euroneuro.2018.03.017  0.176
2023 van Amsterdam J, van den Brink W. The effect of alcohol use on smoking cessation: A systematic review. Alcohol (Fayetteville, N.Y.). PMID 36690220 DOI: 10.1016/j.alcohol.2022.12.003  0.175
2023 de Zeeuw TI, Brunt TM, van Amsterdam J, van de Ven K, van den Brink W. Anabolic Androgenic Steroid Use Patterns and Steroid Use Disorders in a Sample of Male Gym Visitors. European Addiction Research. 1-10. PMID 36731448 DOI: 10.1159/000528256  0.175
2010 Blanken P, Hendriks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction (Abingdon, England). 105: 300-8. PMID 19922517 DOI: 10.1111/j.1360-0443.2009.02754.x  0.175
2006 Van den Brink W, Montgomery SA, Van Ree JM, van Zwieten-Boot BJ. ECNP consensus meeting March 2003 guidelines for the investigation of efficacy in substance use disorders. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 16: 224-30. PMID 16442270 DOI: 10.1016/j.euroneuro.2005.12.003  0.175
2023 Guiraud J, Addolorato G, Aubin HJ, Bachelot S, Batel P, de Bejczy A, Benyamina A, Caputo F, Couderc M, Dematteis M, Goudriaan AE, Gual A, Lecoustey S, Lesch OM, Maremmani I, ... ... van den Brink W, et al. Sodium Oxybate for Alcohol Dependence: A Network Meta-Regression Analysis Considering Population Severity at Baseline and Treatment Duration. Alcohol and Alcoholism (Oxford, Oxfordshire). PMID 36617267 DOI: 10.1093/alcalc/agac070  0.174
2015 Van den Berg JF, Van den Brink W, Kist N, Hermes JS, Kok RM. Social factors and readmission after inpatient detoxification in older alcohol-dependent patients. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 24: 661-6. PMID 26300471 DOI: 10.1111/ajad.12287  0.174
2016 Kronenberg LM, Goossens PJ, van Busschbach JT, van Achterberg T, van den Brink W. Burden and Expressed Emotion of Caregivers in Cases of Adult Substance Use Disorder with and Without Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder. International Journal of Mental Health and Addiction. 14: 49-63. PMID 26798327 DOI: 10.1007/s11469-015-9567-9  0.173
2020 Slobodin O, Blankers M, Kapitány-Fövény M, Kaye S, Berger I, Johnson B, Demetrovics Z, van den Brink W, van de Glind G. Differential Diagnosis in Patients with Substance Use Disorder and/or Attention-Deficit/Hyperactivity Disorder Using Continuous Performance Test. European Addiction Research. 1-11. PMID 32074617 DOI: 10.1159/000506334  0.173
2010 Sizoo B, van den Brink W, Koeter M, Gorissen van Eenige M, van Wijngaarden-Cremers P, van der Gaag RJ. Treatment seeking adults with autism or ADHD and co-morbid substance use disorder: prevalence, risk factors and functional disability. Drug and Alcohol Dependence. 107: 44-50. PMID 19786328 DOI: 10.1016/j.drugalcdep.2009.09.003  0.173
2024 Black N, Chung S, Tisdale C, Fialho LS, Aramrattana A, Assanangkornchai S, Blaszczynski A, Bowden-Jones H, van den Brink W, Brown A, Brown QL, Cottler LB, Elsasser M, Ferri M, Florence M, et al. An International, Multidisciplinary Consensus Set of Patient-Centered Outcome Measures for Substance-Related and Addictive Disorders. Journal of Clinical Medicine. 13. PMID 38610919 DOI: 10.3390/jcm13072154  0.172
2006 Dom G, De Wilde B, Hulstijn W, van den Brink W, Sabbe B. Behavioural aspects of impulsivity in alcoholics with and without a cluster-B personality disorder. Alcohol and Alcoholism (Oxford, Oxfordshire). 41: 412-20. PMID 16782972 DOI: 10.1093/Alcalc/Agl030  0.172
2011 Merkx MJ, Schippers GM, Koeter MW, Vuijk PJ, Oudejans SC, Stam RK, van den Brink W. Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive validity. Addictive Behaviors. 36: 570-5. PMID 21236585 DOI: 10.1016/j.addbeh.2010.12.021  0.172
2013 van der Pol P, Liebregts N, de Graaf R, Ten Have M, Korf DJ, van den Brink W, van Laar M. Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction (Abingdon, England). 108: 1459-69. PMID 23530710 DOI: 10.1111/add.12196  0.171
2018 Raposo Pereira F, McMaster MTB, Polderman N, de Vries YDAT, van den Brink W, van Wingen GA. Adverse effects of GHB-induced coma on long-term memory and related brain function. Drug and Alcohol Dependence. 190: 29-36. PMID 29966850 DOI: 10.1016/j.drugalcdep.2018.05.019  0.17
2022 Guiraud J, Addolorato G, Antonelli M, Aubin HJ, de Bejczy A, Benyamina A, Cacciaglia R, Caputo F, Dematteis M, Ferrulli A, Goudriaan AE, Gual A, Lesch OM, Maremmani I, Mirijello A, ... ... van den Brink W, et al. Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology (Oxford, England). 2698811221104063. PMID 35796481 DOI: 10.1177/02698811221104063  0.17
2014 Kaye S, Gilsenan J, Young JT, Carruthers S, Allsop S, Degenhardt L, van de Glind G, van den Brink W. Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. Drug and Alcohol Dependence. 144: 70-7. PMID 25193717 DOI: 10.1016/j.drugalcdep.2014.08.008  0.169
2013 van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Facilitators and barriers in treatment seeking for cannabis dependence. Drug and Alcohol Dependence. 133: 776-80. PMID 24035185 DOI: 10.1016/j.drugalcdep.2013.08.011  0.169
2014 Matthys F, Stes S, van den Brink W, Joostens P, Möbius D, Tremmery S, Sabbe B. Guideline for Screening, Diagnosis and Treatment of ADHD in Adults with Substance Use Disorders International Journal of Mental Health and Addiction. 12: 629-647. DOI: 10.1007/S11469-014-9496-Z  0.169
2024 Romero P, Czakó A, van den Brink W, Demetrovics Z. Psychedelic-assisted therapy for people with gambling disorder? Journal of Behavioral Addictions. PMID 38421388 DOI: 10.1556/2006.2024.00004  0.169
2007 Roozen HG, de Waart R, van den Brink W. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. European Addiction Research. 13: 201-6. PMID 17851241 DOI: 10.1159/000104882  0.168
2019 van Emmerik-van Oortmerssen K, Vedel E, Kramer FJ, Blankers M, Dekker JJM, van den Brink W, Schoevers RA. Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: Results of a randomized clinical trial. Drug and Alcohol Dependence. 197: 28-36. PMID 30769263 DOI: 10.1016/J.Drugalcdep.2018.12.023  0.168
2022 Vorspan F, Brousse G, Van Den Brink W. Editorial: Dual disorders (addictive and concomitant psychiatric disorders): Mechanisms and treatment. Frontiers in Psychiatry. 13: 975674. PMID 35982937 DOI: 10.3389/fpsyt.2022.975674  0.167
2019 van Amsterdam JGC, Benschop A, van Binnendijk S, Snijder MB, Lok A, Schene AH, Derks EM, van den Brink W. A Comparison of Excessive Drinking, Binge Drinking and Alcohol Dependence in Ethnic Minority Groups in the Netherlands: The HELIUS Study. European Addiction Research. 1-11. PMID 31812961 DOI: 10.1159/000504881  0.167
2023 Guiraud J, van den Brink W. Letter to the Editors regarding 'A Meta-Regression of Trial Features Predicting the Effects of Alcohol Use Disorder Pharmacotherapies on Drinking Outcomes in Randomized Clinical Trials: A Secondary Data Analysis'. Alcohol and Alcoholism (Oxford, Oxfordshire). 58: 688-689. PMID 37794756 DOI: 10.1093/alcalc/agad065  0.167
2018 Herbrink M, Nuijten M, Nuijen B, Huitema ADR, Beijnen JH, Hendriks VM, Blanken P, Janmohamed A, van den Brink W. Pharmacokinetics of Sustained-Release Oral Dexamphetamine Sulfate in Cocaine and Heroin-Dependent Patients. Journal of Clinical Psychopharmacology. 38: 212-217. PMID 29620701 DOI: 10.1097/Jcp.0000000000000862  0.166
2015 van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of Psychopharmacology (Oxford, England). 29: 254-63. PMID 25586398 DOI: 10.1177/0269881114565142  0.166
2011 Ingenhoven TJ, van den Brink W, Passchier J, Duivenvoorden HJ. Treatment-disrupting behaviors during psychotherapy of patients with personality disorders: the predictive power of psychodynamic personality diagnosis. Journal of Psychiatric Practice. 17: 21-34. PMID 21266891 DOI: 10.1097/01.pra.0000393841.25723.70  0.166
2015 Kronenberg LM, Verkerk-Tamminga R, Goossens PJ, van den Brink W, van Achterberg T. Personal recovery in individuals diagnosed with substance use disorder (SUD) and co-occurring attention deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD). Archives of Psychiatric Nursing. 29: 242-8. PMID 26165980 DOI: 10.1016/j.apnu.2015.04.006  0.165
2007 Storosum JG, Wohlfarth T, Schene A, Elferink A, van Zwieten BJ, van den Brink W. Magnitude of effect of lithium in short-term efficacy studies of moderate to severe manic episode. Bipolar Disorders. 9: 793-8. PMID 18076528 DOI: 10.1111/j.1399-5618.2007.00445.x  0.165
2014 Derks EM, Vink JM, Willemsen G, van den Brink W, Boomsma DI. Genetic and environmental influences on the relationship between adult ADHD symptoms and self-reported problem drinking in 6024 Dutch twins. Psychological Medicine. 44: 2673-83. PMID 24957628 DOI: 10.1017/S0033291714000361  0.165
2010 Sizoo B, van den Brink W, Franke B, Vasquez AA, van Wijngaarden-Cremers P, van der Gaag RJ. Do candidate genes discriminate patients with an autism spectrum disorder from those with attention deficit/hyperactivity disorder and is there an effect of lifetime substance use disorders? The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 11: 699-708. PMID 20446882 DOI: 10.3109/15622975.2010.480985  0.164
1999 de Vos JW, Ufkes JG, van den Brink W, van Brussel GH, de Wolff FA. Craving patterns in methadone maintenance treatment with dextromoramide as adjuvant. Addictive Behaviors. 24: 707-13. PMID 10574310 DOI: 10.1016/S0306-4603(98)00081-1  0.164
2013 Merkx MJ, Schippers GM, Koeter MW, Vuijk PJ, Poch M, Kronemeijer H, van den Brink W. Predictive validity of treatment allocation guidelines on drinking outcome in alcohol-dependent patients. Addictive Behaviors. 38: 1691-8. PMID 23254220 DOI: 10.1016/j.addbeh.2012.09.011  0.163
2020 van den Brink W. Baclofen: A Game Changer in the Treatment of Alcohol Dependence. Alcohol and Alcoholism (Oxford, Oxfordshire). 55: 46-47. PMID 32031207 DOI: 10.1093/alcalc/agz085  0.162
2005 Rehm J, Room R, van den Brink W, Kraus L. Problematic drug use and drug use disorders in EU countries and Norway: an overview of the epidemiology. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 15: 389-97. PMID 15955677 DOI: 10.1016/J.Euroneuro.2005.04.004  0.162
2015 Sizoo BB, van der Gaag RJ, van den Brink W. Temperament and character as endophenotype in adults with autism spectrum disorders or attention deficit/hyperactivity disorder. Autism : the International Journal of Research and Practice. 19: 400-8. PMID 24535690 DOI: 10.1177/1362361314522352  0.162
2009 Sizoo BB, van den Brink W, Gorissen-van Eenige M, Koeter MW, van Wijngaarden-Cremers PJ, van der Gaag RJ. Using the Autism-spectrum quotient to discriminate Autism Spectrum Disorder from ADHD in adult patients with and without comorbid Substance Use Disorder. Journal of Autism and Developmental Disorders. 39: 1291-7. PMID 19396535 DOI: 10.1007/s10803-009-0743-2  0.162
2010 Koeter MW, van den Brink W, Lehert P. Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence. Journal of Substance Abuse Treatment. 39: 218-26. PMID 20627222 DOI: 10.1016/j.jsat.2010.06.002  0.162
2004 Van Den Bosch LM, Verheul R, Langeland W, Van Den Brink W. Trauma, dissociation, and posttraumatic stress disorder in female borderline patients with and without substance abuse problems. The Australian and New Zealand Journal of Psychiatry. 37: 549-55. PMID 14511082 DOI: 10.1046/j.1440-1614.2003.01199.x  0.162
1999 Verheul R, van den Brink W, Koeter MW. Temporal stability of diagnostic criteria for antisocial personality disorder in male alcohol dependent patients. Journal of Personality Disorders. 12: 316-31. PMID 9891286 DOI: 10.1521/PEDI.1998.12.4.316  0.161
2005 Klous MG, Van den Brink W, Van Ree JM, Beijnen JH. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug and Alcohol Dependence. 80: 283-95. PMID 15916865 DOI: 10.1016/J.Drugalcdep.2005.04.008  0.161
2007 van Nimwegen L, de Haan L, van Beveren N, van den Brink W, Linszen D. [Adolescence, schizophrenia and drug abuse: interactive vulnerability. A hypothesis]. Tijdschrift Voor Psychiatrie. 49: 169-78. PMID 17370223  0.161
2022 Tuithof M, Ten Have M, van Dorsselaer S, de Beurs D, van den Brink W, de Graaf R, Vermunt JK. Identification of Latent Alcohol Use Groups and Transitions over Time Using a 9-Year Follow-Up Study in the Adult General Population. European Addiction Research. 1-11. PMID 36122566 DOI: 10.1159/000526137  0.16
2015 Kronenberg LM, Goossens PJ, van Etten DM, van Achterberg T, van den Brink W. Need for care and life satisfaction in adult substance use disorder patients with and without attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD). Perspectives in Psychiatric Care. 51: 4-15. PMID 24410895 DOI: 10.1111/ppc.12056  0.16
2020 van Binnendijk S, van Amsterdam JGC, Snijder MB, Schene AH, Derks EM, van den Brink W. Contribution of Alcohol and Nicotine Dependence to the Prevalence of Depressed Mood in Different Ethnic Groups in The Netherlands: The HELIUS Study. Journal of Dual Diagnosis. 1-14. PMID 32552497 DOI: 10.1080/15504263.2020.1772526  0.16
2015 Nuijten M, Blanken P, van den Brink W, Hendriks V. Modafinil in the treatment of crack-cocaine dependence in the Netherlands: Results of an open-label randomised controlled feasibility trial. Journal of Psychopharmacology (Oxford, England). 29: 678-87. PMID 25922424 DOI: 10.1177/0269881115582151  0.16
2016 Blanken P, Hendriks VM, Huijsman IA, van Ree JM, van den Brink W. Efficacy of cocaine contingency management in heroin-assisted treatment: Results of a randomized controlled trial. Drug and Alcohol Dependence. PMID 27177805 DOI: 10.1016/j.drugalcdep.2016.04.018  0.16
2015 van den Brink W, Strang J, Gual A, Sørensen P, Jensen TJ, Mann K. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme. Expert Opinion On Drug Safety. 14: 495-504. PMID 25652768 DOI: 10.1517/14740338.2015.1011619  0.16
2013 van de Glind G, Van Emmerik-van Oortmerssen K, Carpentier PJ, Levin FR, Koeter MW, Barta C, Kaye S, Skutle A, Franck J, Konstenius M, Bu ET, Moggi F, Dom G, Demetrovics Z, Fatséas M, ... ... van den Brink W, et al. The International ADHD in Substance Use Disorders Prevalence (IASP) study: background, methods and study population. International Journal of Methods in Psychiatric Research. 22: 232-44. PMID 24022983 DOI: 10.1002/Mpr.1397  0.159
2014 Nuijten M, Blanken P, van den Brink W, Hendriks V. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence. 138: 177-84. PMID 24629631 DOI: 10.1016/j.drugalcdep.2014.02.024  0.159
2005 de Bruijn C, van den Brink W. Validity of the one-criterion threshold for an alcohol abuse diagnosis. The American Journal of Psychiatry. 162: 2400; author reply 2. PMID 16330621 DOI: 10.1176/appi.ajp.162.12.2400  0.159
2007 Merkx MJ, Schippers GM, Koeter MJ, Vuijk PJ, Oudejans S, de Vries CC, van den Brink W. Allocation of substance use disorder patients to appropriate levels of care: feasibility of matching guidelines in routine practice in Dutch treatment centres. Addiction (Abingdon, England). 102: 466-74. PMID 17298655 DOI: 10.1111/j.1360-0443.2006.01716.x  0.158
2017 Gomes T, Juurlink DN, Mamdani MM, Paterson JM, van den Brink W. Prevalence and characteristics of opioid-related deaths involving alcohol in Ontario, Canada. Drug and Alcohol Dependence. PMID 28867560 DOI: 10.1016/J.Drugalcdep.2017.07.008  0.158
2004 Vreugdenhil C, Doreleijers TA, Vermeiren R, Wouters LF, van den Brink W. Psychiatric disorders in a representative sample of incarcerated boys in the Netherlands. Journal of the American Academy of Child and Adolescent Psychiatry. 43: 97-104. PMID 14691365 DOI: 10.1097/00004583-200401000-00019  0.157
2010 Schilt T, Koeter MW, Smal JP, Gouwetor MN, van den Brink W, Schmand B. Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users. Psychopharmacology. 207: 583-91. PMID 19823808 DOI: 10.1007/s00213-009-1688-z  0.157
2006 Helzer JE, van den Brink W, Guth SE. Should there be both categorical and dimensional criteria for the substance use disorders in DSM-V? Addiction (Abingdon, England). 101: 17-22. PMID 16930157 DOI: 10.1111/j.1360-0443.2006.01587.x  0.156
2017 van den Brink W. ICD-11 Gaming Disorder: Needed and just in time or dangerous and much too early? Journal of Behavioral Addictions. 1-3. PMID 28816496 DOI: 10.1556/2006.6.2017.040  0.155
2015 Skutle A, Bu ETH, Jellestad FK, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, Auriacombe M, ... ... van den Brink W, et al. Early developmental, temperamental and educational problems in 'substance use disorder' patients with and without ADHD. Does ADHD make a difference? Addictive Behaviors Reports. 2: 13-18. PMID 29531989 DOI: 10.1016/J.Abrep.2015.03.001  0.155
2013 Van Den Brink W. 'As needed' nalmefene: A new treatment for alcohol dependence | Nalmefeen 'zo nodig': Een nieuwe behandeling voor alcoholafhankelijkheid Tijdschrift Voor Psychiatrie. 55: 294-295.  0.155
2006 Zinkstok J, Schmitz N, van Amelsvoort T, de Win M, van den Brink W, Baas F, Linszen D. The COMT val158met polymorphism and brain morphometry in healthy young adults. Neuroscience Letters. 405: 34-9. PMID 16857316 DOI: 10.1016/J.Neulet.2006.06.034  0.155
2005 Blanken P, Hendriks VM, Koeter MW, van Ree JM, van den Brink W. Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction (Abingdon, England). 100: 89-95. PMID 15598196 DOI: 10.1111/j.1360-0443.2005.00937.x  0.154
2015 Fischer B, Kuganesan S, Gallassi A, Malcher-Lopes R, van den Brink W, Wood E. Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. The International Journal On Drug Policy. PMID 26500166 DOI: 10.1016/j.drugpo.2015.09.005  0.153
2003 Langeland W, Draijer N, van den Brink W. Assessment of lifetime physical and sexual abuse in treated alcoholics. Validity of the Addiction Severity Index. Addictive Behaviors. 28: 871-81. PMID 12788262 DOI: 10.1016/S0306-4603(01)00297-0  0.152
1991 Ormel J, Koeter MW, van den Brink W, van de Willige G. Recognition, management, and course of anxiety and depression in general practice. Archives of General Psychiatry. 48: 700-6. PMID 1883252 DOI: 10.1001/ARCHPSYC.1991.01810320024004  0.152
2016 Konstenius M, Leifman A, van Emmerik-van Oortmerssen K, van de Glind G, Franck J, Moggi F, Ramos-Quiroga JA, Levin FR, Carpentier PJ, Skutle A, Bu ET, Kaye S, Demetrovics Z, Barta C, Auriecomb M, ... ... van den Brink W, et al. Childhood trauma exposure in substance use disorder patients with and without ADHD. Addictive Behaviors. 65: 118-124. PMID 27816036 DOI: 10.1016/J.Addbeh.2016.10.016  0.152
2011 van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regulatory Toxicology and Pharmacology : Rtp. 59: 423-9. PMID 21256914 DOI: 10.1016/j.yrtph.2011.01.006  0.152
2012 van Amsterdam JG, van Laar M, Brunt TM, van den Brink W. Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands. Regulatory Toxicology and Pharmacology : Rtp. 63: 55-63. PMID 22440552 DOI: 10.1016/j.yrtph.2012.03.005  0.151
2012 Ingenhoven TJ, Duivenvoorden HJ, Passchier J, van den Brink W. Treatment duration and premature termination of psychotherapy in personality disorders: predictive performance of psychodynamic personality functioning. Journal of Psychiatric Practice. 18: 172-86. PMID 22617082 DOI: 10.1097/01.pra.0000415074.43744.29  0.151
2005 de Wildt WA, Lehert P, Schippers GM, Nakovics H, Mann K, van den Brink W. Investigating the structure of craving using structural equation modeling in analysis of the obsessive-compulsive drinking scale: a multinational study. Alcoholism, Clinical and Experimental Research. 29: 509-16. PMID 15834215 DOI: 10.1097/01.ALC.0000158844.35608.48  0.15
2016 van den Brink W. Dimensional models and neurobiology of personality disorders. Acta Neuropsychiatrica. 11: 1-4. PMID 26976096 DOI: 10.1017/s0924270800036279  0.15
1993 DeJong CA, van den Brink W, Jansen JA. Sex role stereotypes and clinical judgement: how therapists view their alcoholic patients. Journal of Substance Abuse Treatment. 10: 383-9. PMID 8411297  0.149
2012 Brunt TM, Koeter MW, Niesink RJ, van den Brink W. Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users. Psychopharmacology. 220: 751-62. PMID 21993879 DOI: 10.1007/s00213-011-2529-4  0.149
2018 Randesi M, van den Brink W, Levran O, Yuferov V, Blanken P, van Ree JM, Ott J, Kreek MJ. Dopamine gene variants in opioid addiction: comparison of dependent patients, nondependent users and healthy controls. Pharmacogenomics. 19: 95-104. PMID 29210332 DOI: 10.2217/Pgs-2017-0134  0.148
2003 van den Brink W, Hendriks VM, Blanken P, Koeter MW, van Zwieten BJ, van Ree JM. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. Bmj (Clinical Research Ed.). 327: 310. PMID 12907482 DOI: 10.1136/bmj.327.7410.310  0.147
2012 van Dijk D, Koeter MW, Hijman R, Kahn RS, van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophrenia Research. 137: 50-7. PMID 22313726 DOI: 10.1016/J.Schres.2012.01.016  0.147
2007 van der Zanden BP, Dijkgraaf MG, Blanken P, van Ree JM, van den Brink W. Patterns of acquisitive crime during methadone maintenance treatment among patients eligible for heroin assisted treatment. Drug and Alcohol Dependence. 86: 84-90. PMID 16806740 DOI: 10.1016/j.drugalcdep.2006.05.021  0.147
2019 Vermeulen JM, Wootton RE, Treur JL, Sallis HM, Jones HJ, Zammit S, van den Brink W, Goodwin GM, de Haan L, Munafò MR. Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study. The British Journal of Psychiatry : the Journal of Mental Science. 1-7. PMID 31526406 DOI: 10.1192/bjp.2019.202  0.146
1996 Havenaar JM, Van den Brink W, Van den Bout J, Kasyanenko AP, Poelijoe NW, Wholfarth T, Meijler-Iljina LI. Mental health problems in the Gomel region (Belarus): an analysis of risk factors in an area affected by the Chernobyl disaster. Psychological Medicine. 26: 845-55. PMID 8817720 DOI: 10.1017/S0033291700037879  0.143
2015 Skutle A, Bu ETH, Jellestad FK, van Emmerik-van Oortmerssen K, Dom G, Verspreet S, Carpentier PJ, Ramos-Quiroga JA, Franck J, Konstenius M, Kaye S, Demetrovics Z, Barta C, Fatséas M, Auriacombe M, ... ... van den Brink W, et al. Early developmental, temperamental and educational problems in 'substance use disorder' patients with and without ADHD: Does ADHD make a difference? Addictive Behaviors Reports. 2: 13-18. DOI: 10.1016/j.abrep.2015.03.001  0.142
2002 Fischer B, Rehm J, Kirst M, Casas M, Hall W, Krausz M, Metrebian N, Reggers J, Uchtenhagen A, van den Brink W, van Ree JM. Heroin-assisted treatment as a response to the public health problem of opiate dependence. European Journal of Public Health. 12: 228-34. PMID 12232964 DOI: 10.1093/Eurpub/12.3.228  0.142
2001 Nobels FR, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, de Jong FH, Lamberts SW. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma. European Journal of Endocrinology. 143: 615-21. PMID 11078985 DOI: 10.1530/EJE.0.1430615  0.142
2015 van Amsterdam J, Nabben T, van den Brink W. Recreational nitrous oxide use: Prevalence and risks. Regulatory Toxicology and Pharmacology : Rtp. PMID 26496821 DOI: 10.1016/j.yrtph.2015.10.017  0.141
2005 Klous MG, Rook EJ, Hillebrand MJ, van den Brink W, van Ree JM, Beijnen JH. Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program. Journal of Analytical Toxicology. 29: 564-9. PMID 16168180 DOI: 10.1093/Jat/29.6.564  0.141
2022 Ágoston C, Urbán R, Horváth Z, van den Brink W, Demetrovics Z. Self-Medication of ADHD Symptoms: Does Caffeine Have a Role? Frontiers in Psychiatry. 13: 813545. PMID 35185656 DOI: 10.3389/fpsyt.2022.813545  0.141
2011 Soyka M, Kranzler HR, van den Brink W, Krystal J, Möller HJ, Kasper S. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry. 12: 160-87. PMID 21486104 DOI: 10.3109/15622975.2011.561872  0.14
2018 Vermeulen JM, Schirmbeck F, Blankers M, van Tricht M, Bruggeman R, van den Brink W, de Haan L. Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study. The American Journal of Psychiatry. appiajp201818010069. PMID 30138044 DOI: 10.1176/appi.ajp.2018.18010069  0.14
2013 Dom G, van den Brink W. [Developments in pharmacotherapy: personalised pharmacotherapy?]. Tijdschrift Voor Psychiatrie. 55: 899-906. PMID 24242151  0.14
2011 Buster MC, van den Brink W, van Brussel GH, van Ree JM. Influence of treatment with inhalable heroin on pulmonary function. European Addiction Research. 17: 136-8. PMID 21422758 DOI: 10.1159/000324482  0.14
2007 Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J, van den Brink W. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. Journal of Urban Health : Bulletin of the New York Academy of Medicine. 84: 552-62. PMID 17562183 DOI: 10.1007/s11524-007-9198-y  0.14
2014 van den Berg JF, Hermes JS, van den Brink W, Blanken P, Kist N, Kok RM. Physical and mental health and social functioning in older alcohol-dependent inpatients: the role of age of onset. European Addiction Research. 20: 226-32. PMID 24776814 DOI: 10.1159/000357322  0.139
2010 Blanken P, van den Brink W, Hendriks VM, Huijsman IA, Klous MG, Rook EJ, Wakelin JS, Barendrecht C, Beijnen JH, van Ree JM. Heroin-assisted treatment in the Netherlands: History, findings, and international context. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 20: S105-58. PMID 20362236 DOI: 10.1016/S0924-977X(10)70001-8  0.139
2006 Couwenbergh C, van den Brink W, Zwart K, Vreugdenhil C, van Wijngaarden-Cremers P, van der Gaag RJ. Comorbid psychopathology in adolescents and young adults treated for substance use disorders: a review. European Child & Adolescent Psychiatry. 15: 319-28. PMID 16648966 DOI: 10.1007/s00787-006-0535-6  0.138
2002 Rietdijk EA, van den Bosch LM, Verheul R, Koeter MW, van den Brink W. Predicting self-damaging and suicidal behaviors in female borderline patients: reasons for living, coping, and depressive personality disorder. Journal of Personality Disorders. 15: 512-20. PMID 11778393 DOI: 10.1521/PEDI.15.6.512.19188  0.138
2015 Benschop A, Liebregts N, van der Pol P, Schaap R, Buisman R, van Laar M, van den Brink W, de Graaf R, Korf DJ. Reliability and validity of the Marijuana Motives Measure among young adult frequent cannabis users and associations with cannabis dependence. Addictive Behaviors. 40: 91-5. PMID 25240105 DOI: 10.1016/j.addbeh.2014.09.003  0.137
2013 Liebregts N, van der Pol P, Van Laar M, de Graaf R, van den Brink W, Korf DJ. The Role of Study and Work in Cannabis Use and Dependence Trajectories among Young Adult Frequent Cannabis Users. Frontiers in Psychiatry. 4: 85. PMID 23950748 DOI: 10.3389/fpsyt.2013.00085  0.137
2003 Roozen HG, Kerkhof AJ, van den Brink W. Experiences with an outpatient relapse program (community reinforcement approach) combined with naltrexone in the treatment of opioid-dependence: effect on addictive behaviors and the predictive value of psychiatric comorbidity. European Addiction Research. 9: 53-8. PMID 12644730 DOI: 10.1159/000068808  0.137
2004 Langeland W, van den Brink W. Child sexual abuse and substance use disorders: role of psychiatric comorbidity. The British Journal of Psychiatry : the Journal of Mental Science. 185: 353. PMID 15458998 DOI: 10.1192/BJP.185.4.353  0.136
2022 Demetrovics Z, van den Brink W, Paksi B, Horváth Z, Maraz A. Relating Compulsivity and Impulsivity With Severity of Behavioral Addictions: A Dynamic Interpretation of Large-Scale Cross-Sectional Findings. Frontiers in Psychiatry. 13: 831992. PMID 35782446 DOI: 10.3389/fpsyt.2022.831992  0.135
2013 van der Pol P, Liebregts N, de Graaf R, Korf DJ, van den Brink W, van Laar M. Reliability and validity of the Severity of Dependence Scale for detecting cannabis dependence in frequent cannabis users. International Journal of Methods in Psychiatric Research. 22: 138-43. PMID 23670783 DOI: 10.1002/mpr.1385  0.135
2015 Van den Brink W. Substance use disorders, trauma, and PTSD European Journal of Psychotraumatology. 6: 27632. DOI: 10.3402/ejpt.v6.27632  0.134
2002 Langeland W, van den Brink W, Draijer N. Trauma, trauma-related distress, and perceived parental dysfunction: associations with severity of drinking problems in treated alcoholics. The Journal of Nervous and Mental Disease. 190: 337-40. PMID 12011616 DOI: 10.1097/00005053-200205000-00012  0.134
2015 Vorspan F, Fortias M, Zerdazi EH, Karsinti E, Bloch V, Lépine JP, Bellivier F, Brousse G, van den Brink W, Derks EM. Self-reported cue-induced physical symptoms of craving as an indicator of cocaine dependence. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. PMID 26541796 DOI: 10.1111/ajad.12303  0.134
2006 Vreugdenhil C, van den Brink W, Ferdinand R, Wouters L, Doreleijers T. The ability of YSR scales to predict DSM/DISC-C psychiatric disorders among incarcerated male adolescents. European Child & Adolescent Psychiatry. 15: 88-96. PMID 16463011 DOI: 10.1007/s00787-006-0497-8  0.134
2019 Yuferov V, Randesi M, Butelman ER, van den Brink W, Blanken P, van Ree JM, Ott J, Kreek MJ. Association of variants of prodynorphin promoter 68-bp repeats in caucasians with opioid dependence diagnosis: Effect on age trajectory of heroin use. Neuroscience Letters. 704: 100-105. PMID 30936032 DOI: 10.1016/J.Neulet.2019.03.038  0.133
2022 Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. Journal of Psychopharmacology (Oxford, England). 2698811221116926. PMID 36017784 DOI: 10.1177/02698811221116926  0.132
2010 Brunt TM, van Laar M, Niesink RJ, van den Brink W. The relationship of quality and price of the psychostimulants cocaine and amphetamine with health care outcomes. Drug and Alcohol Dependence. 111: 21-9. PMID 20439138 DOI: 10.1016/j.drugalcdep.2010.02.023  0.132
2010 Colins O, Vermeiren R, Vreugdenhil C, van den Brink W, Doreleijers T, Broekaert E. Psychiatric disorders in detained male adolescents: a systematic literature review. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 55: 255-63. PMID 20416149  0.131
2014 van der Pol P, Liebregts N, Brunt T, van Amsterdam J, de Graaf R, Korf DJ, van den Brink W, van Laar M. Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction (Abingdon, England). 109: 1101-9. PMID 24628797 DOI: 10.1111/add.12508  0.131
2019 Raposo Pereira F, McMaster MTB, de Vries YDAT, Polderman N, van den Brink W, van Wingen GA. Influence of Gamma-Hydroxybutyric Acid-Use and Gamma-Hydroxybutyric Acid-Induced Coma on Affect and the Affective Network. European Addiction Research. 1-9. PMID 30999293 DOI: 10.1159/000497381  0.131
2016 Randesi M, van den Brink W, Levran O, Blanken P, Butelman ER, Yuferov V, da Rosa JC, Ott J, van Ree JM, Kreek MJ. Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. Drug and Alcohol Dependence. 168: 164-169. PMID 27664554 DOI: 10.1016/J.Drugalcdep.2016.08.634  0.13
2003 Franken IH, Hendriksa VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. Addictive Behaviors. 27: 675-85. PMID 12201376 DOI: 10.1016/S0306-4603(01)00201-5  0.129
2005 Marissen MA, Franken IH, Blanken P, Hendriks VM, van den Brink W. The relation between social desirability and different measures of heroin craving. Journal of Addictive Diseases. 24: 91-103. PMID 16368659  0.129
1998 Wohlfarth T, van den Brink W. Social class and substance use disorders: the value of social class as distinct from socioeconomic status. Social Science & Medicine (1982). 47: 51-8. PMID 9683378 DOI: 10.1016/S0277-9536(98)00011-2  0.128
2024 Breeksema JJ, Niemeijer A, Krediet E, Karsten T, Kamphuis J, Vermetten E, van den Brink W, Schoevers R. Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study. Scientific Reports. 14: 2929. PMID 38316896 DOI: 10.1038/s41598-024-53188-9  0.126
2008 van den Brink W, Schippers GM. [Addiction and care for addicts]. Tijdschrift Voor Psychiatrie. 50: 91-7. PMID 19067306  0.126
2006 Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Current Clinical Pharmacology. 1: 109-18. PMID 18666382 DOI: 10.2174/157488406775268219  0.126
2021 Van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opinion On Drug Safety. 1-12. PMID 34176409 DOI: 10.1080/14740338.2021.1949454  0.125
2022 van Amsterdam JG, Nabben T, van den Brink W. Increasing recreational nitrous oxide use: Should we worry? A narrative review. Journal of Psychopharmacology (Oxford, England). 2698811221082442. PMID 35678512 DOI: 10.1177/02698811221082442  0.125
2003 Verheul R, Van Den Bosch LM, Koeter MW, De Ridder MA, Stijnen T, Van Den Brink W. Dialectical behaviour therapy for women with borderline personality disorder: 12-month, randomised clinical trial in The Netherlands. The British Journal of Psychiatry : the Journal of Mental Science. 182: 135-40. PMID 12562741 DOI: 10.1192/bjp.182.2.135  0.124
2017 van Amsterdam J, van der Velde B, Schulte M, van den Brink W. Causal Factors of Increased Smoking in ADHD: A Systematic Review. Substance Use & Misuse. 1-14. PMID 29039714 DOI: 10.1080/10826084.2017.1334066  0.124
2005 Termorshuizen F, Krol A, Prins M, Geskus R, van den Brink W, van Ameijden EJ. Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug and Alcohol Dependence. 79: 231-40. PMID 16002032 DOI: 10.1016/j.drugalcdep.2005.01.013  0.124
2010 van Nimwegen-Campailla L, van Beveren N, Laan W, van den Brink W, Linszen D, de Haan L. Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis. Pharmacopsychiatry. 43: 281. PMID 20839158 DOI: 10.1055/S-0030-1263172  0.123
2002 Buster M, Rook L, van Brussel GH, van Ree J, van den Brink W. Chasing the dragon, related to the impaired lung function among heroin users. Drug and Alcohol Dependence. 68: 221-8. PMID 12234652 DOI: 10.1016/S0376-8716(02)00193-X  0.123
2023 Breeksema JJ, Niemeijer A, Kuin B, Veraart J, Vermetten E, Kamphuis J, van den Brink W, Schoevers R. Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study. Psychopharmacology. PMID 37222753 DOI: 10.1007/s00213-023-06388-6  0.123
1993 Wohlfarth TD, van den Brink W, Ormel J, Koeter MW, Oldehinkel AJ. The relationship between social dysfunctioning and psychopathology among primary care attenders. The British Journal of Psychiatry : the Journal of Mental Science. 163: 37-44. PMID 8353697 DOI: 10.1192/BJP.163.1.37  0.123
2015 van Amsterdam J, van den Brink W. The Misuse of Prescription Opioids: A Threat for Europe? Current Drug Abuse Reviews. 8: 3-14. PMID 26084418  0.123
2023 van Amsterdam J, Pierce M, van den Brink W. Predictors and motives of polydrug use in opioid users. A narrative review. Current Opinion in Psychiatry. PMID 37191648 DOI: 10.1097/YCO.0000000000000875  0.122
2006 Rook EJ, van Ree JM, van den Brink W, Hillebrand MJ, Huitema AD, Hendriks VM, Beijnen JH. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic & Clinical Pharmacology & Toxicology. 98: 86-96. PMID 16433897 DOI: 10.1111/J.1742-7843.2006.Pto_233.X  0.122
2004 Klous MG, Nuijen B, van den Brink W, van Ree JM, Beijnen JH. Development and manufacture of diacetylmorphine/caffeine sachets for inhalation via 'chasing the dragon' by heroin addicts. Drug Development and Industrial Pharmacy. 30: 775-84. PMID 15491055 DOI: 10.1081/Ddc-120040223  0.122
2005 Bammer G, van den Brink W, Gschwend P, Hendriks V, Rehm J. What can the Swiss and Dutch trials tell us about the potential risks associated with heroin prescribing? Drug and Alcohol Review. 22: 363-71. PMID 15385231 DOI: 10.1080/0959523031000154517  0.121
2007 Popma A, Vermeiren R, Geluk CA, Rinne T, van den Brink W, Knol DL, Jansen LM, van Engeland H, Doreleijers TA. Cortisol moderates the relationship between testosterone and aggression in delinquent male adolescents. Biological Psychiatry. 61: 405-11. PMID 16950214 DOI: 10.1016/j.biopsych.2006.06.006  0.12
2006 van Veen E, Aerdts S, van den Brink W. Critical Care. 10: P458. DOI: 10.1186/CC4805  0.12
2024 van Amsterdam J, Gresnigt F, van den Brink W. Cardiovascular Risks of Simultaneous Use of Alcohol and Cocaine-A Systematic Review. Journal of Clinical Medicine. 13. PMID 38592322 DOI: 10.3390/jcm13051475  0.12
2024 van Amsterdam J, van den Brink W. Explaining the high mortality among opioid-cocaine co-users compared to opioid-only users. A systematic review. Journal of Addictive Diseases. 1-11. PMID 38504419 DOI: 10.1080/10550887.2024.2331522  0.12
2024 van den Brink W, van Amsterdam J. The pros and cons of banning electronic cigarettes. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 82: 53-54. PMID 38490085 DOI: 10.1016/j.euroneuro.2024.01.012  0.12
2011 Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. Journal of Psychopharmacology (Oxford, England). 25: 1543-7. PMID 20826554 DOI: 10.1177/0269881110378370  0.12
2007 Vervaeke HK, Korf DJ, Benschop A, van den Brink W. How to find future ecstasy-users: targeted and snowball sampling in an ethically sensitive context. Addictive Behaviors. 32: 1705-13. PMID 17188817 DOI: 10.1016/j.addbeh.2006.11.008  0.117
2009 Couwenbergh C, Van Der Gaag RJ, Koeter M, De Ruiter C, Van den Brink W. Screening for substance abuse among adolescents validity of the CAGE-AID in youth mental health care. Substance Use & Misuse. 44: 823-34. PMID 19444724 DOI: 10.1080/10826080802484264  0.117
1997 Boersma F, Eefsting JA, van den Brink W, van Tilburg W. Characteristics of non-responders and the impact of non-response on prevalence estimates of dementia. International Journal of Epidemiology. 26: 1055-62. PMID 9363528 DOI: 10.1093/ije/26.5.1055  0.117
1998 Havenaar J, Rumyantzeva G, Kasyanenko A, Kaasjager K, Westermann A, van den Brink W, van den Bout J, Savelkoul J. Health effects of the Chernobyl disaster: illness or illness behavior? A comparative general health survey in two former Soviet regions. Environmental Health Perspectives. 1533-7. PMID 9467078 DOI: 10.1289/EHP.97105S61533  0.116
2002 van den Bosch LM, Verheul R, Schippers GM, van den Brink W. Dialectical Behavior Therapy of borderline patients with and without substance use problems. Implementation and long-term effects. Addictive Behaviors. 27: 911-23. PMID 12369475  0.116
2005 Storosum JG, Wohlfarth T, Gispen-de Wied CC, Linszen DH, Gersons BP, van Zwieten BJ, van den Brink W. Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. The American Journal of Psychiatry. 162: 799-802. PMID 15800158 DOI: 10.1176/Appi.Ajp.162.4.799  0.115
2015 Uhl A, Hunt G, van den Brink W, Stimson GV. How credible are international databases for understanding substance use and related problems? The International Journal On Drug Policy. 26: 119-21. PMID 25477287 DOI: 10.1016/j.drugpo.2014.10.014  0.115
2004 Storosum JG, Fouwels A, Gispen-de Wied CC, Wohlfarth T, van Zwieten BJ, van den Brink W. How real are patients in placebo-controlled studies of acute manic episode? European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14: 319-23. PMID 15163442 DOI: 10.1016/j.euroneuro.2003.10.003  0.115
2006 Haasen C, van den Brink W. Innovations in agonist maintenance treatment of opioid-dependent patients. Current Opinion in Psychiatry. 19: 631-6. PMID 17012944 DOI: 10.1097/01.yco.0000245759.13997.9d  0.115
2022 Breeksema JJ, Niemeijer A, Kuin B, Veraart J, Kamphuis J, Schimmel N, van den Brink W, Vermetten E, Schoevers R. Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study. Frontiers in Psychiatry. 13: 948115. PMID 36506427 DOI: 10.3389/fpsyt.2022.948115  0.115
2010 van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. European Addiction Research. 16: 202-7. PMID 20606445 DOI: 10.1159/000317249  0.115
2012 Nuijten M, Blanken P, Van Der Hoorn B, Van Den Brink W, Hendriks V. A randomised controlled trial of outpatient versus inpatient integrated treatment of dual diagnosis patients: A failed but informative study Mental Health and Substance Use: Dual Diagnosis. 5: 132-147. DOI: 10.1080/17523281.2011.628947  0.115
2018 Strous JFM, van den Brink W. [New indications for existing drugs; repurposing in psychiatry and addiction medicine]. Nederlands Tijdschrift Voor Geneeskunde. 162. PMID 30020573  0.114
1997 de Vos JW, Ufkes JG, van Brussel GH, van den Brink W. Craving despite extremely high methadone dosage. Drug and Alcohol Dependence. 40: 181-4. PMID 8861396 DOI: 10.1016/0376-8716(95)01207-9  0.113
2019 Marees AT, Gamazon ER, Gerring Z, Vorspan F, Fingal J, van den Brink W, Smit DJA, Verweij KJH, Kranzler HR, Sherva R, Farrer L, Gelernter J, Derks EM. Post-GWAS analysis of six substance use traits improves the identification and functional interpretation of genetic risk loci. Drug and Alcohol Dependence. 107703. PMID 31785998 DOI: 10.1016/J.Drugalcdep.2019.107703  0.112
2001 Storosum JG, van Zwieten BJ, Vermeulen HD, Wohlfarth T, van den Brink W. Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. European Psychiatry : the Journal of the Association of European Psychiatrists. 16: 327-35. PMID 11585712 DOI: 10.1016/S0924-9338(01)00587-9  0.112
1990 Koeter MW, van den Brink W, Ormel J. Chronic psychiatric complaints and the General Health Questionnaire. The British Journal of Psychiatry : the Journal of Mental Science. 155: 186-90. PMID 2597913 DOI: 10.1192/BJP.155.2.186  0.112
2006 Rook EJ, van Zanten AP, Van den Brink W, van Ree JM, Beijnen JH. Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin. Drug and Alcohol Dependence. 85: 185-90. PMID 16765536 DOI: 10.1016/J.Drugalcdep.2006.04.013  0.112
2015 Liebregts N, van der Pol P, van Laar M, de Graaf R, van den Brink W, Korf DJ. The role of leisure and delinquency in frequent cannabis use and dependence trajectories among young adults. The International Journal On Drug Policy. 26: 143-52. PMID 25171910 DOI: 10.1016/j.drugpo.2014.07.014  0.111
2005 Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. Bmj (Clinical Research Ed.). 330: 1297. PMID 15933353 DOI: 10.1136/bmj.330.7503.1297  0.111
2015 Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, Lintzeris N, Bell J, Pirona A, Oviedo-Joekes E, Simon R, Metrebian N. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction†. The British Journal of Psychiatry : the Journal of Mental Science. 207: 5-14. PMID 26135571 DOI: 10.1192/bjp.bp.114.149195  0.111
2006 Van den Brink W, Haasen C. Evidenced-based treatment of opioid-dependent patients. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 51: 635-46. PMID 17052031  0.111
2015 van Amsterdam J, Phillips L, Henderson G, Bell J, Bowden-Jones O, Hammersley R, Ramsey J, Taylor P, Dale-Perera A, Melichar J, van den Brink W, Nutt D. Ranking the harm of non-medically used prescription opioids in the UK. Regulatory Toxicology and Pharmacology : Rtp. PMID 26382614 DOI: 10.1016/J.Yrtph.2015.09.014  0.111
2006 van der Zanden BP, Dijkgraaf MG, Blanken P, de Borgie CA, van Ree JM, van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug and Alcohol Dependence. 82: 111-8. PMID 16168573 DOI: 10.1016/j.drugalcdep.2005.08.012  0.11
2011 El Marroun H, Hudziak JJ, Tiemeier H, Creemers H, Steegers EA, Jaddoe VW, Hofman A, Verhulst FC, van den Brink W, Huizink AC. Intrauterine cannabis exposure leads to more aggressive behavior and attention problems in 18-month-old girls. Drug and Alcohol Dependence. 118: 470-4. PMID 21470799 DOI: 10.1016/J.Drugalcdep.2011.03.004  0.109
2018 van Amsterdam J, Vervloet J, de Weert G, Buwalda VJA, Goudriaan AE, van den Brink W. Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia. Harm Reduction Journal. 15: 47. PMID 30236118 DOI: 10.1186/s12954-018-0253-7  0.109
2008 Braakman MH, Kortmann FA, van den Brink W, Verkes RJ. Posttraumatic stress disorder with secondary psychotic features: neurobiological findings. Progress in Brain Research. 167: 299-302. PMID 18037029 DOI: 10.1016/S0079-6123(07)67027-7  0.108
2009 Wohlfarth T, Linszen D, Van Den Brink W. Blinding in clozapine trials: a problem and a potential solution. International Journal of Methods in Psychiatric Research. 18: 185-8. PMID 19701925 DOI: 10.1002/Mpr.291  0.108
2021 Schimmel N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review. Psychopharmacology. PMID 34812901 DOI: 10.1007/s00213-021-06027-y  0.107
2017 Caraci F, Enna SJ, Zohar J, Racagni G, Zalsman G, van den Brink W, Kasper S, Koob GF, Pariante CM, Piazza PV, Yamada K, Spedding M, Drago F. A New Nomenclature for Classifying Psychotropic Drugs. British Journal of Clinical Pharmacology. PMID 28401576 DOI: 10.1111/Bcp.13302  0.106
2009 Braakman MH, Kortmann FA, van den Brink W. Validity of 'post-traumatic stress disorder with secondary psychotic features': a review of the evidence. Acta Psychiatrica Scandinavica. 119: 15-24. PMID 18764840 DOI: 10.1111/j.1600-0447.2008.01252.x  0.106
2003 Storosum JG, van Zwieten BJ, Wohlfarth T, de Haan L, Khan A, van den Brink W. Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Archives of General Psychiatry. 60: 365-8. PMID 12695313 DOI: 10.1001/ARCHPSYC.60.4.365  0.106
2003 Havenaar JM, de Wilde EJ, van den Bout J, Drottz-Sjöberg BM, van den Brink W. Perception of risk and subjective health among victims of the Chernobyl disaster. Social Science & Medicine (1982). 56: 569-72. PMID 12570974 DOI: 10.1016/S0277-9536(02)00062-X  0.106
2010 Zandi T, Havenaar JM, Smits M, Limburg-Okken AG, van Es H, Cahn W, Algra A, Kahn RS, van den Brink W. First contact incidence of psychotic disorders among native Dutch and Moroccan immigrants in the Netherlands: influence of diagnostic bias. Schizophrenia Research. 119: 27-33. PMID 20332065 DOI: 10.1016/J.Schres.2010.02.1059  0.106
2004 Storosum JG, Elferink AJ, van Zwieten BJ, van den Brink W, Huyser J. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry. 37: 32-6. PMID 14750046 DOI: 10.1055/S-2004-815472  0.105
2017 Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health. 107: 1277. PMID 28700290 DOI: 10.2105/AJPH.2017.303818a  0.103
2017 Fischer B, Russell C, Sabioni P, van den Brink W, Le Foll B, Hall W, Rehm J, Room R. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health. e1-e12. PMID 28644037 DOI: 10.2105/Ajph.2017.303818  0.103
2023 van Amsterdam J, Burgess N, van den Brink W. Legal Approaches to New Psychoactive Substances: First Empirical Findings. European Addiction Research. 1-10. PMID 37557091 DOI: 10.1159/000531503  0.103
2018 van Amsterdam J, Vorspan F, Snijder MB, van den Brink W, Schene AH, Stronks K, Galenkamp H, Derks EM. Use of the Fagerström test to assess differences in the degree of nicotine dependence in smokers from five ethnic groups: The HELIUS study. Drug and Alcohol Dependence. 194: 197-204. PMID 30447512 DOI: 10.1016/j.drugalcdep.2018.10.011  0.103
2006 Rook EJ, Huitema AD, van den Brink W, van Ree JM, Beijnen JH. Population pharmacokinetics of heroin and its major metabolites. Clinical Pharmacokinetics. 45: 401-17. PMID 16584286 DOI: 10.2165/00003088-200645040-00005  0.102
1996 Eefsting JA, Boersma F, Van den Brink W, Van Tilburg W. Differences in prevalence of dementia based on community survey and general practitioner recognition. Psychological Medicine. 26: 1223-30. PMID 8931168 DOI: 10.1017/S0033291700035947  0.102
Hide low-probability matches.